Details of the Drug

General Information of Drug (ID: DMZ7XNQ)

Drug Name
Tacrolimus
Synonyms
Advagraf; Fujimycin; Graceptor; Modigraf; Prograf; Protopic; Protopy; Tacarolimus; Tsukubaenolide; Tacrolimus anhydrous; FK 506; FK5; FK506; FR 900506; FR900506; K506; L 679934; Advagraf (TN); FR-900506; Fk-506; L-679934; LCP-Tacro; Prograf (TN); Protopic (TN); Tacrolimus (INN); Tacrolimus (Prograf); Tacrolimus (anhydrous); (-)-FK 506; 15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone; 8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
Indication
Disease Entry ICD 11 Status REF
Graft-versus-host disease 4B24 Approved [1]
Hepatosplenic T-cell lymphoma N.A. Approved [1]
Kidney transplant rejection NE84 Approved [1]
Large granular lymphocytic leukemia 2A90.1 Approved [1]
Leukemia N.A. Approved [1]
Lupus nephritis 4A40.0Y Approved [1]
MALT lymphoma N.A. Approved [1]
Myeloproliferative neoplasm 2A20 Approved [1]
Nodal marginal zone lymphoma 2A85.0 Approved [1]
Organ transplant rejection NE84 Approved [2]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified N.A. Approved [1]
Recurrent adult burkitt lymphoma 2A85.6 Approved [1]
Small intestine lymphoma N.A. Approved [1]
Splenic marginal zone lymphoma N.A. Approved [1]
Testicular lymphoma N.A. Approved [1]
Ocular allergy 4A81 Phase 3 [2]
Classic Hodgkin lymphoma N.A. Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Immunosuppressive Agents
Affected Organisms
Humans and other mammals
ATC Code
: Tacrolimus
D11AF: Wart and anti-corn preparations
D11A: OTHER DERMATOLOGICAL PREPARATIONS
D11: OTHER DERMATOLOGICAL PREPARATIONS
D: DERMATOLOGICALS
D11AH01: Tacrolimus
D11AH: Agents for dermatitis, excluding corticosteroids
D11A: OTHER DERMATOLOGICAL PREPARATIONS
D11: OTHER DERMATOLOGICAL PREPARATIONS
D: DERMATOLOGICALS
L04AD02: Tacrolimus
L04AD: Calcineurin inhibitors
L04A: IMMUNOSUPPRESSANTS
L04: IMMUNOSUPPRESSANTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04AD02: Tacrolimus
L04AD: Calcineurin inhibitors
L04A: IMMUNOSUPPRESSANTS
L04: IMMUNOSUPPRESSANTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 804
Logarithm of the Partition Coefficient (xlogp) 2.7
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 12
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.7 mL/min/kg [4]
Elimination
0.5% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 35 hours (in adult healthy volunteers), 19 hours (in kidney transplant patients), 12 hours (in liver transplants patients), and 24 hours (in heart transplant patients) [4]
Metabolism
The drug is metabolized via the CYP3A4 and secondarily by CYP3A5 [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.24329 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.01% [4]
Vd
The volume of distribution (Vd) of drug is 2.6 +/- 2.1 L/kg []
Water Solubility
The ability of drug to dissolve in water is measured as 0.008 mg/mL [3]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Nephropathy toxic Not Available PPP3R1 OTGQNFJQ [7]
Chemical Identifiers
Formula
C44H69NO12
IUPAC Name
(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-prop-2-enyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone
Canonical SMILES
C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC
InChI
InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1
InChIKey
QJJXYPPXXYFBGM-LFZNUXCKSA-N
Cross-matching ID
PubChem CID
445643
ChEBI ID
CHEBI:61049
CAS Number
104987-11-3
UNII
Y5L2157C4J
DrugBank ID
DB00864
TTD ID
D06OMK
VARIDT ID
DR00406
INTEDE ID
DR1524
ACDINA ID
D00648
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Calcineurin (PPP3CA) TTA4LDE PP2BA_HUMAN Inhibitor [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [11]
NADPH-cytochrome P450 reductase (CPR) DE3N2FM NCPR_HUMAN Substrate [12]
Ribosomal 23S RNA methyltransferase Erm (erm) DEW6V07 A0A5N1AHF6_CORAY Substrate [13]
Ribosomal 23S RNA methyltransferase Erm (erm) DEA65D8 A0A381KDL2_CORJE Substrate [13]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Actin-related protein 2/3 complex subunit 5 (ARPC5) OTFNMMDL ARPC5_HUMAN Gene/Protein Processing [14]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Gene/Protein Processing [15]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Drug Response [16]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Gene/Protein Processing [17]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Gene/Protein Processing [18]
C-C chemokine receptor type 3 (CCR3) OT6GBUFA CCR3_HUMAN Gene/Protein Processing [19]
C-C motif chemokine 5 (CCL5) OTSCA5CK CCL5_HUMAN Gene/Protein Processing [19]
Cadherin-1 (CDH1) OTFJMXPM CADH1_HUMAN Gene/Protein Processing [20]
Calcineurin subunit B type 1 (PPP3R1) OTGQNFJQ CANB1_HUMAN Drug Response [7]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Protein Interaction/Cellular Processes [15]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Graft-versus-host disease
ICD Disease Classification 4B24
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Calcineurin (PPP3CA) DTT PPP3CA 5.29E-01 1.74E-03 9.99E-03
P-glycoprotein 1 (ABCB1) DTP P-GP 2.00E-01 2.57E-02 6.18E-02
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 5.05E-02 4.52E-01 5.39E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 8.67E-01 -3.83E-03 -1.24E-02
NADPH-cytochrome P450 reductase (CPR) DME POR 8.69E-02 -1.76E-01 -3.46E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 137 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JK1 CTRP2 5.0276 8.4215 4.0115 11.8327
MEC1 CTRP2 5.3585 7.4137 4.806 7.7966
JM1 CTRP2 6.8045 12.8556 3.3684 10.804
SEM CTRP2 -6.5926 14.3522 -10.5972 62.9765
Ri-1 CTRP2 0.9437 27.2509 -8.9677 45.5195
A4/Fukuda CTRP2 1.9729 15.3807 -2.2534 38.33
KMS-34 CTRP2 3.0937 7.4623 2.4003 23.2904
Pfeiffer CTRP2 3.1891 7.0436 2.6529 22.0854
KMS-21-BM CTRP2 3.3844 8.2347 2.4081 22.4247
SU-DHL-8 CTRP2 3.8564 5.7691 3.7469 16.0919
Mono-Mac-1 CTRP2 3.8778 7.4029 3.2624 17.8185
BL-70 CTRP2; CTRP1 4.0525 5.1598 4.0388 14.4511
KMS-28BM CTRP2 4.066 7.7471 3.3249 17.0556
L-540 CTRP2 4.1204 7.0753 3.6459 15.6742
KMS-12-BM CTRP2 4.1721 14.9555 0.0408 27.9545
Daudi CTRP2 4.2696 7.044 3.8176 14.5986
TALL-1 [Human adult T-ALL] CTRP2 4.2908 7.4146 3.6967 15.0024
NCO2 CTRP2 4.2928 9.0755 2.9784 17.8059
P12-Ichikawa CTRP2 4.3189 8.2625 3.3691 16.2042
Ku812 CTRP2; CTRP1 4.4161 5.9961 4.3061 12.3582
EoL-1 CTRP2 4.4417 5.676 4.3954 11.9634
SU-DHL-6 CTRP2 4.4451 7.7892 3.7039 14.5546
KE-97 CTRP2; CTRP1 4.4889 18.0284 -1.1887 30.1389
SUP-T11 CTRP2 4.5061 6.298 4.3256 12.0115
SU-DHL-1 CTRP2 4.5503 8.3163 3.5816 14.7614
MOLT-16 CTRP2 4.5963 16.1298 -0.1518 27.45
DEL CTRP2 4.5985 5.6418 4.5676 10.8635
ST486 CTRP2 4.6184 7.0052 4.2057 12.1339
DB CTRP2 4.6617 6.6739 4.3741 11.3721
EM-2 CTRP2 4.6746 7.2643 4.1627 12.1439
NOMO-1 CTRP1 4.6799 6.6757 4.3932 24.0282
JURL-MK1 CTRP2 4.6852 7.3036 4.1579 12.1338
CML-T1 CTRP2 4.6882 7.6302 4.0242 12.6486
SU-DHL-5 CTRP1 4.7463 5.2273 4.7458 20.9056
F-36P CTRP2 4.7857 6.9193 4.4171 10.8553
GA-10 CTRP2 4.829 6.9705 4.4435 10.6327
NALM-6 CTRP2 4.8471 6.2636 4.7075 9.5895
MOLM-13 CTRP2 4.8511 6.011 4.7762 9.3305
M-07e CTRP2 4.8761 5.964 4.8132 9.1215
Peer CTRP2 4.8968 9.7357 3.2608 15.1917
WSU-DLCL2 CTRP2; CTRP1 4.9379 6.0084 4.871 8.7231
NU-DUL-1 CTRP2; CTRP1 4.9674 13.248 1.6082 21.2833
L-428 CTRP2 5.0111 6.4835 4.8177 8.6954
KMS-20 CTRP2 5.0581 6.6438 4.8123 8.5794
DND-41 CTRP2 5.084 7.3708 4.5451 9.546
AML-193 CTRP2 5.0905 5.8001 5.0709 7.5394
RPMI-8226 CTRP1 5.1022 6.4555 4.9259 17.167
NU-DHL-1 CTRP2 5.1142 7.0443 4.7153 8.7965
GDM-1 CTRP2; CTRP1 5.1325 9.1464 3.7691 12.5695
EB1 CTRP2 5.1497 9.3665 3.6794 12.8961
KE-37 CTRP2 5.1681 6.2149 5.0715 7.2932
THP-1 CTRP2; CTRP1 5.1745 6.6645 4.9297 7.803
KMS-11 CTRP1 5.3087 6.6443 5.081 12.815
KMS-18 CTRP2 5.3666 6.7565 5.0986 6.618
TF-1 CTRP2 5.3681 11.1854 2.9897 15.2028
KYO-1 CTRP2 5.3737 13.323 1.9343 19.2187
JJN-3 CTRP2 5.4008 6.5719 5.207 6.1061
RS4;11 CTRP2 5.4053 31.0622 -6.8933 36.4956
Kasumi-2 CTRP2 5.4249 6.126 5.3745 5.4145
MOTN-1 CTRP2 5.4333 6.5029 5.2674 5.7843
OCI-Ly3 CTRP2 5.4613 6.4912 5.3018 5.5743
Mono-Mac-6 CTRP2 5.477 11.8853 2.7402 15.9531
RPMI-8402 CTRP2 5.4804 13.1002 2.1391 18.2378
KO52 CTRP2 5.4805 11.5404 2.9145 15.2569
RCH-ACV CTRP2 5.5066 21.4748 -2.0165 29.6713
RL CTRP2 5.5428 6.1067 5.5072 4.5754
HL-60 CTRP2 5.5599 6.1927 5.5051 4.5295
SIG-M5 CTRP2 5.5757 6.042 5.5553 4.3025
LP-1 CTRP2; CTRP1 5.5848 8.0538 4.7262 7.5736
HuNS1 CTRP2 5.5873 6.7496 5.3331 5.1046
SET-2 CTRP2 5.6068 6.1418 5.5689 4.1562
OCI-AML-3 CTRP2; CTRP1 5.6175 6.2435 5.5538 4.178
OCI-AML-5 CTRP2 5.6244 6.1816 5.5784 4.0676
SUP-HD1 CTRP2 5.642 7.9349 4.8378 6.9803
JeKo-1 CTRP2 5.665 6.1162 5.6379 3.7295
HPB-ALL CTRP2 5.6825 7.5374 5.0678 5.9376
ME1 CTRP2 5.7089 11.1908 3.2902 13.2544
HuT 78 CTRP2 5.7265 6.8162 5.4474 4.2867
OCI-M1 CTRP2 5.7475 6.1762 5.7139 3.2021
MOLM-6 CTRP2 5.7745 13.6343 2.1286 17.6489
SU-DHL-4 CTRP2; CTRP1 5.7781 8.8954 4.492 8.1165
KMS-26 CTRP2 5.7921 10.7259 3.5946 11.8299
PL21 CTRP2; CTRP1 5.7965 9.144 4.3853 8.5238
OCI-Ly19 CTRP2 5.8009 7.1588 5.3625 4.4466
K-562 CTRP2 5.8075 8.2045 4.86 6.5148
REC-1 CTRP2 5.8763 8.8027 4.6257 7.347
OPM-2 CTRP2 5.9116 29.7953 -5.8326 34.5881
Granta-519 CTRP2 5.941 6.8815 5.6299 3.0162
MOLP-8 CTRP2 5.9492 15.2778 1.4566 19.6634
U-937 CTRP2; CTRP1 5.9754 8.4698 4.8788 6.0769
Karpas-422 CTRP2 5.9771 6.6898 5.756 2.4134
Mino CTRP2 5.9787 12.7793 2.7303 14.937
HT CTRP2; CTRP1 5.9909 9.8228 4.2175 8.8234
EJM CTRP2; CTRP1 6.0489 6.917 5.7144 2.419
L-1236 CTRP2 6.0571 10.2621 4.0548 9.3726
SU-DHL-10 CTRP2 6.1235 8.0924 5.1954 4.4422
AMO1 CTRP2; CTRP1 6.2264 7.9221 5.3672 3.5162
Karpas-620 CTRP2 6.2442 7.4248 5.6305 2.3731
KCL-22 CTRP2 6.2487 13.0904 2.8016 14.1167
MHH-CALL-3 CTRP2 6.2997 10.1728 4.3024 7.8603
Hs 611.T CTRP2 6.3039 7.5197 5.6313 2.2597
MOLM-16 CTRP2; CTRP1 6.3117 7.4978 5.6484 2.1734
SKM-1 CTRP2; CTRP1 6.3164 8.5198 5.1422 4.2943
L-363 CTRP2 6.4586 8.1431 5.4416 2.7841
U266B1 CTRP2 6.5436 8.7642 5.1987 3.6545
MHH-CALL-4 CTRP2 6.6251 9.85 4.7229 5.5041
SR CTRP2 6.7775 9.0644 5.2232 3.1769
SUP-B15 CTRP2 6.9082 19.9034 -0.0643 22.4174
MC116 CTRP2; CTRP1 6.9712 9.1035 5.3374 2.4356
HD-MY-Z CTRP2 7.0053 12.2691 3.8146 8.63
JVM-3 CTRP2 7.0298 12.9983 3.4721 9.9871
JVM-2 CTRP2 7.0472 9.7134 5.0969 3.2932
OCI-Ly10 CTRP2; CTRP1 7.0567 9.367 5.2686 2.5934
LAMA-84 CTRP2 7.0678 15.0596 2.4778 13.8289
MOLP-2 CTRP2 7.3615 9.1704 5.543 1.2127
Kasumi-1 CTRP2 7.3684 9.8384 5.2458 2.2901
KMS-27 CTRP2 7.3785 9.4763 5.4168 1.6431
RPMI-6666 CTRP2 7.4056 9.2883 5.5156 1.2657
Raji CTRP2 7.5415 13.4527 3.629 8.5089
KM-H2 CTRP2 7.558 23.4561 -1.3175 24.3855
MM1.S CTRP2 7.5737 13.4661 3.6457 8.3914
NB4 CTRP2 7.6101 12.5407 4.1215 6.4188
CMK CTRP2 7.6108 9.675 5.4581 1.2733
HEL CTRP2 7.7155 12.4276 4.2483 5.757
NCI-H929 CTRP2 7.7544 11.9158 4.5182 4.6306
Ki-JK CTRP2 7.8002 19.3983 0.8893 18.0254
Karpas-299 CTRP2 7.8385 13.0132 4.0508 6.3713
MV4-11 CTRP2 7.8642 14.6508 3.2757 9.4094
P3HR-1 CTRP2; CTRP1 8.0083 9.9369 5.5463 0.7101
Jurkat CTRP2 8.0473 18.9513 1.2978 16.2994
P31/FUJ CTRP2 8.1977 15.098 3.2932 8.8378
HDLM-2 CTRP2 8.4125 16.1178 2.9494 9.84
OCI-AML-2 CTRP2 8.4649 18.7357 1.7121 14.2337
PF-382 CTRP2 8.7291 18.4491 2.0411 12.6859
KHM-1B CTRP2 9.0147 17.85 2.5286 10.5277
EHEB CTRP2 9.2417 19.5574 1.8623 12.5452
KMM-1 CTRP2 10.847 27.1742 -0.7049 17.867
⏷ Show the Full List of 137 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE8 CTRP2 5.6211 7.3715 5.0868 6.0069
TE15 CTRP2 5.7023 7.2865 5.2062 5.3232
TE-6 CTRP2 5.2139 6.5294 5.0214 7.343
TE-5 CTRP2 5.3696 7.0892 4.9617 7.1465
OE21 CTRP2 5.5649 6.8359 5.273 5.4008
KYSE-150 CTRP2 5.6318 6.1354 5.5976 3.9764
TE-4 CTRP2 5.7952 7.1023 5.3838 4.3733
TE-11 CTRP2 5.8402 7.6899 5.1427 5.2644
KYSE-140 CTRP2; CTRP1 5.9849 8.0891 5.0766 5.2265
KYSE-410 CTRP2; CTRP1 5.9925 8.1373 5.0593 5.2832
KYSE-30 CTRP2 6.053 7.1069 5.6245 2.785
KYSE-510 CTRP2 6.1884 7.9051 5.3441 3.6873
TE-14 CTRP2 6.5091 9.3123 4.9001 4.9637
COLO 680N CTRP2 6.5719 8.7268 5.2386 3.4406
KYSE-70 CTRP2 7.3736 12.1573 4.141 6.6959
EC-GI-10 CTRP2 7.4005 12.8898 3.8024 8.0316
KYSE-180 CTRP2 7.418 10.1048 5.1532 2.5839
TE-1 CTRP2 7.8903 10.1056 5.4197 1.1643
TE-9 CTRP2 7.9916 9.6945 5.6343 0.4947
TE-10 CTRP2 8.0366 10.6406 5.2675 1.5349
OE19 CTRP2 8.1443 9.2809 5.8448 0.0811
KYSE-520 CTRP2 8.5059 10.6911 5.4718 0.6292
KYSE-450 CTRP2; CTRP1 9.1739 14.9452 3.995 4.8974
⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 36 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
N2a-PK1 CTRP2 8.2734 10.073 5.6094 0.4233
KP-4 CTRP2 5.1694 6.5757 4.9569 7.7141
SU.86.86 CTRP2 5.1988 6.1874 5.1125 7.0514
SW1990 CTRP2 5.6107 6.9814 5.2559 5.3497
Panc 04.03 CTRP2 5.668 6.8502 5.3727 4.7357
KP-2 CTRP2 5.7082 6.1775 5.6708 3.4779
Panc 10.05 CTRP2; CTRP1 5.7232 7.4915 5.1288 5.5907
HuP-T3 CTRP2 5.748 6.5162 5.5983 3.6349
Panc 03.27 CTRP2; CTRP1 5.7523 6.4785 5.6179 3.5473
SNU-410 CTRP2 5.7573 8.6189 4.6099 7.6689
PSN1 CTRP2 5.766 6.7975 5.4959 3.9913
DAN-G CTRP2 5.7759 6.6959 5.5512 3.7451
MIA PaCa-2 CTRP2 5.794 6.2789 5.7353 2.9837
Panc 08.13 CTRP2 5.8404 6.9857 5.483 3.8587
PaTu 8988s CTRP2 6.094 6.9034 5.7621 2.1209
Hs 766T CTRP2 6.113 7.5003 5.482 3.2574
BxPC-3 CTRP2 6.1972 9.1855 4.7112 6.3366
AsPC-1 CTRP2 6.2324 8.246 5.2102 4.1663
Capan-2 CTRP1 6.299 9.7264 3.7818 8.8712
Panc 05.04 CTRP2 7.2726 10.2719 4.9813 3.4434
KP-3 CTRP2; CTRP1 7.2816 10.3638 4.9435 3.5817
HuP-T4 CTRP2; CTRP1 7.5501 13.0585 3.8277 7.6951
PK-45H CTRP2 7.6978 10.4449 5.1659 2.2168
QGP-1 CTRP2; CTRP1 7.716 13.3258 3.8152 7.4928
SNU-213 CTRP2 7.8233 9.5873 5.6009 0.674
SUIT-2 CTRP2; CTRP1 7.8287 10.0848 5.3968 1.2877
YAPC CTRP2 7.9704 9.1659 5.8217 0.1401
HPAC CTRP2; CTRP1 7.9732 9.6632 5.6385 0.4939
PaTu 8988t CTRP2 7.9873 27.938 -3.2111 27.4881
PaTu 8902 CTRP2; CTRP1 8.0224 9.3084 5.7907 0.1727
PK-59 CTRP2 8.0617 11.3183 4.9836 2.4943
TCC-Pan2 CTRP2 8.1794 11.0979 5.146 1.8143
CFPAC-1 CTRP2; CTRP1 8.1797 11.5119 4.9644 2.4426
Panc 02.03 CTRP2 8.1854 10.9382 5.2179 1.5711
L3.3 CTRP2 8.3158 12.4963 4.5997 3.627
HPAF-II CTRP2 8.3354 10.7218 5.3826 0.9581
⏷ Show the Full List of 36 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 48 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SH4 CTRP2 7.6538 9.6592 5.4876 1.3113
WM115 CTRP2 5.4014 6.3188 5.2955 5.7723
WM266-4 CTRP2 5.5217 6.0104 5.5024 4.6588
RVH-421 CTRP2 5.6571 6.1016 5.6324 3.7738
WM88 CTRP2 5.6734 6.1363 5.6427 3.6861
MeWo CTRP2 5.6871 6.3203 5.6057 3.7795
WM983B CTRP2 5.7027 6.3261 5.6207 3.6779
Hs 940.T CTRP2 5.7263 6.4081 5.6172 3.6227
SK-MEL-3 CTRP2 5.7513 6.1352 5.7276 3.1414
UACC-62 CTRP2 5.7693 6.1555 5.7427 3.0316
Hs 895.T CTRP2 5.7911 6.325 5.7168 3.0608
CJM [Human melanoma] CTRP2 5.7987 6.4659 5.6722 3.2092
HT-144 CTRP2 5.8129 6.2604 5.7618 2.8297
Hs 294T CTRP2 5.8318 6.194 5.8014 2.6285
IGR-37 CTRP2 5.9107 6.6467 5.7102 2.7633
Hs 839.T CTRP2 5.9148 6.4897 5.784 2.4588
WT2-iPS CTRP2 5.9334 6.4128 5.8358 2.2056
Hs 934.T CTRP2 6.1823 7.1606 5.7111 2.153
COLO 741 CTRP1 6.2576 8.5869 4.2938 4.782
IGR-1 CTRP2 6.2619 7.2843 5.7151 1.9837
UACC-257 CTRP2 6.3708 7.3611 5.7619 1.5958
Hs 688(A).T CTRP2 6.4208 7.652 5.6558 1.9546
Hs 944.T CTRP2; CTRP1 6.7569 9.0004 5.2397 3.1406
SK-MEL-5 CTRP2; CTRP1 6.7907 8.5837 5.4648 2.1751
SK-MEL-1 CTRP2; CTRP1 6.8311 8.5806 5.4933 2.0053
A-375 CTRP2; CTRP1 6.9495 8.582 5.5685 1.5598
A101D CTRP2 7.0107 21.9381 -0.9975 24.6074
SK-MEL-28 CTRP2; CTRP1 7.078 7.9164 5.9259 0.2491
Hs 852.T CTRP2; CTRP1 7.443 12.2718 4.1347 6.6154
SK-MEL-2 CTRP2 7.5499 8.6908 5.8303 0.2529
LOX-IMVI CTRP2 7.5838 9.526 5.508 1.1313
Mel Ho CTRP2 7.6581 9.4427 5.5809 0.8426
SK-MEL-30 CTRP2 7.7181 9.7022 5.5024 1.0395
WM1799 CTRP2 7.7206 9.075 5.7562 0.3402
MDA-MB-435S CTRP2 7.7257 8.9735 5.7965 0.254
COLO 792 CTRP2 7.805 12.6645 4.1953 5.8428
K029AX CTRP2 7.8399 9.1795 5.7662 0.2716
SK-MEL-31 CTRP2 7.9759 9.5289 5.6911 0.3727
IGR-39 CTRP2 8.0134 15.1771 3.1256 9.7652
IPC-298 CTRP2 8.1543 9.5286 5.7621 0.1824
Mel JuSo CTRP2 8.1769 9.5967 5.7464 0.2007
G-361 CTRP2; CTRP1 8.2432 15.2337 3.2592 8.9026
WM793 CTRP2 8.496 9.9409 5.7436 0.1336
COLO 800 CTRP2 8.9898 10.7016 5.6585 0.1447
COLO 829 CTRP2 12.6294 29.6975 -0.7119 15.6281
Hs 936.T CTRP2; CTRP1 12.8358 25.8878 1.1905 10.2144
A2058 CTRP2 13.9225 32.595 -1.2428 15.4356
HMCB CTRP2 14.112 27.4381 1.2329 8.8147
⏷ Show the Full List of 48 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 CTRP2 5.6195 6.9619 5.2736 5.2561
Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
IMR-32 CTRP2 3.2623 12.8998 0.1752 29.9388
SK-N-BE(2) CTRP2 5.1668 6.5274 4.9713 7.6674
NH-6 CTRP2 5.6361 6.1751 5.5928 3.9803
SK-N-DZ CTRP2 5.7053 6.8568 5.4078 4.4998
SK-N-FI CTRP2 5.7489 18.308 -0.2277 25.1279
Kelly CTRP2 6.1023 11.5506 3.449 11.7991
CHP-126 CTRP2 7.2957 9.1501 5.5153 1.3741
NB1 CTRP2 7.3463 14.2188 3.1082 10.9052
KP-N-SI9s CTRP2 7.4083 10.6671 4.8831 3.6502
KP-N-YN CTRP2 10.5301 23.7493 0.7266 14.3648
SK-N-SH CTRP2 13.9297 34.646 -2.2043 17.5704
⏷ Show the Full List of 11 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-1079 CTRP2 4.6101 14.3056 0.7618 24.8592
HuCC-T1 CTRP2 5.6922 20.7385 -1.4905 28.2314
SNU-869 CTRP2 5.7967 6.2717 5.7406 2.9559
SNU-308 CTRP2 6.6825 8.9512 5.2101 3.3794
SNU-478 CTRP2 7.5515 9.5366 5.4864 1.2313
HuH-28 CTRP2 8.0903 9.4142 5.7787 0.1736
SNU-1196 CTRP2 8.1642 16.272 2.6996 11.1591
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TC71 CTRP2 5.5497 6.1084 5.5144 4.5281
SaOS-2 CTRP2 5.6016 6.9789 5.2478 5.4054
SK-ES-1 CTRP2 5.6275 6.3577 5.5285 4.2419
MG-63 CTRP2 5.6445 6.1848 5.5995 3.9302
Hs 822.T CTRP2 5.7202 6.0157 5.7133 3.2911
A-673 CTRP2 5.7821 6.2098 5.743 2.9911
CAL-78 CTRP2 5.867 6.4243 5.761 2.6777
SJSA-1 CTRP2 5.9124 7.2672 5.4164 3.9647
Hs 888.T CTRP2 6.0091 7.3103 5.4843 3.4667
SK-N-MC CTRP2 6.2276 9.4799 4.5894 6.7909
MHH-ES-1 CTRP2 7.3478 11.1206 4.6256 4.7652
SW1353 CTRP2 8.5642 10.6933 5.4961 0.5459
U2OS CTRP2 8.8676 10.6821 5.6207 0.2163
HOS CTRP2 8.9153 17.6993 2.5332 10.6528
G-292 clone A141B1 CTRP2 11.0476 21.3623 2.1849 9.1086
⏷ Show the Full List of 15 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 67 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HCC2218 CTRP2 4.6628 6.8238 4.3213 11.568
CAL-85-1 CTRP2 5.1475 6.497 4.9609 7.7625
ZR-75-30 CTRP2 5.5321 6.6171 5.3294 5.2695
SK-BR-3 CTRP2 5.5684 6.7377 5.3184 5.213
AU565 CTRP2 5.5838 7.2376 5.1123 5.9954
KPL-1 CTRP2 5.6243 6.2509 5.5591 4.1379
HCC1500 CTRP2 5.6421 6.3977 5.5303 4.1923
HCC1419 CTRP2 5.7829 6.3812 5.6879 3.1931
T-47D CTRP2 5.7836 7.5481 5.1589 5.3258
MDA-MB-361 CTRP2 5.8385 6.5537 5.6775 3.0808
BT-474 CTRP2 6.0269 7.9332 5.1911 4.6577
CAL-51 CTRP2 6.2653 7.2191 5.7504 1.829
BT-20 CTRP2 6.3066 7.2853 5.7502 1.7551
HCC1428 CTRP2 6.4432 8.376 5.3143 3.343
EFM-192A CTRP2 6.6623 13.9154 2.727 13.6157
MCF-7 CTRP2; CTRP1 6.7416 9.3131 5.0757 3.8408
MDA-MB-468 CTRP2 7.0445 10.6311 4.65 5.12
Hs 578T CTRP2 7.4715 9.814 5.3187 1.9014
HCC1937 CTRP2 7.5298 9.7663 5.3736 1.6423
HCC38 CTRP2 7.6338 12.858 3.9844 6.9362
HMC-1-8 CTRP2 7.6433 11.4617 4.6606 4.2167
CAMA-1 CTRP2 7.7882 9.7609 5.5129 0.9534
MDA-MB-231 CTRP2 7.928 13.3332 3.958 6.6133
HCC1395 CTRP2 7.9575 10.2329 5.4001 1.1733
DU4475 CTRP2 7.965 47.4148 -12.9491 37.5759
HCC202 CTRP2 7.9726 11.7867 4.7173 3.5822
CAL-148 CTRP2 8.0322 9.2898 5.801 0.155
ZR-75-1 CTRP2 8.0576 9.4389 5.7573 0.2163
HCC1143 CTRP2 8.1985 10.8259 5.2723 1.3858
JIMT-1 CTRP2 8.4041 13.9885 3.9615 5.9523
BT-549 CTRP2 8.4516 10.3574 5.5762 0.421
HCC1806 CTRP2 8.5183 10.0493 5.7139 0.1663
HCC1954 CTRP2 8.6534 10.0414 5.765 0.0872
BT 239 CTRP2 4.5894 6.0116 4.4913 11.1594
BT 231 CTRP2 5.1341 7.2359 4.6551 8.9793
BT 228 CTRP2 5.2854 5.9722 5.2545 6.2769
BT 248 CTRP2 5.3189 6.389 5.1833 6.4317
BT 187 CTRP2 5.4056 9.7986 3.7077 12.1963
BT 139 CTRP2 5.6057 6.0223 5.5906 4.0835
BT 145 CTRP2 5.6297 7.1133 5.2153 5.4648
BT 159 CTRP2 5.739 6.5681 5.5676 3.7784
BT 416 CTRP2 6.1119 10.9916 3.7366 10.5914
BT 428 CTRP2 6.6204 10.5002 4.3962 6.8796
BT 172 CTRP2 6.9319 9.1172 5.3046 2.6206
BT 482 CTRP2 6.9589 11.028 4.3926 6.3194
BT 286 CTRP2 7.032 10.9788 4.4707 5.8785
BT 245 CTRP2 7.1697 9.6734 5.1975 2.7246
BT 271 CTRP2 7.2546 13.5619 3.3638 10.0419
BT164 CTRP2 7.3051 9.0389 5.5698 1.1736
BT 422 CTRP2 7.4057 12.068 4.2074 6.3767
BT 320 CTRP2 7.415 11.6479 4.4176 5.509
BT 444 CTRP2 7.4366 14.7536 2.912 11.5225
BT 333 CTRP2 7.4958 9.6669 5.3985 1.588
BT 498 CTRP2 7.5383 14.5689 3.0788 10.7018
BT 112 CTRP2 7.5572 9.7723 5.3863 1.5702
BT 131 CTRP2 7.621 10.6121 5.0437 2.7588
BT 440 CTRP2 7.6321 11.5746 4.5997 4.4722
BT147 CTRP2 7.6701 11.8664 4.4861 4.872
BT 216 CTRP2 7.6888 12.1104 4.3821 5.2602
BT 179 CTRP2 7.7948 11.9545 4.5263 4.5453
BT 504 CTRP2 7.8248 11.1769 4.908 3.0338
BT 232 CTRP2 7.8348 12.222 4.4259 4.8876
BT 224 CTRP2 7.8765 9.9269 5.4876 0.9654
BT 330 CTRP2 8.0036 9.7084 5.6342 0.4892
BT 359 CTRP2 8.0681 11.6675 4.8297 3.0498
BT 340 CTRP2 8.1839 12.5926 4.4748 4.2529
BT 328 CTRP2 8.3667 13.9775 3.9425 6.0748
⏷ Show the Full List of 67 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-38 CTRP2 7.8701 8.9472 5.8615 0.1088
Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-489 CTRP2 3.1884 11.3556 0.8276 28.3135
SF268 CTRP2 5.3745 6.8323 5.076 6.6841
GB-1 CTRP2 5.4412 6.3799 5.319 5.5677
Daoy CTRP2 5.4505 6.3396 5.3423 5.4538
ONS-76 CTRP2 5.451 6.8186 5.1618 6.1422
SF539 CTRP2 5.4731 6.2185 5.4033 5.1626
U-251MG CTRP2 5.6332 6.4313 5.5086 4.3001
U-118MG CTRP2 5.6392 6.3212 5.5533 4.1149
CAS-1 CTRP2 5.6728 6.1689 5.6343 3.7179
KNS-81 CTRP2 5.6924 6.1187 5.6671 3.5403
Hs 683 CTRP2 5.7057 6.1761 5.6684 3.4943
D283 Med CTRP2 5.7635 6.299 5.6957 3.2206
T98G CTRP2 5.9627 6.6815 5.7458 2.4902
SF126 CTRP2 5.9705 7.0353 5.5837 3.1384
KG-1-C CTRP2 6.0012 6.5173 5.8601 1.9318
A-172 CTRP2 6.4632 8.1059 5.4635 2.6851
KALS-1 CTRP2 6.5434 8.2035 5.4752 2.5045
NMC-G1 CTRP2 6.5621 7.9175 5.6285 1.8439
LN-229 CTRP2; CTRP1 6.5901 8.3097 5.4572 2.5051
42-MG-BA CTRP2 6.6671 8.7205 5.3119 2.9832
SNB-75 CTRP2 6.7039 10.6067 4.4081 6.6841
SW1088 CTRP2 6.9132 19.3398 0.2211 21.6126
Becker CTRP2 7.253 10.4701 4.8735 3.9013
YH-13 CTRP2 7.5772 10.4709 5.082 2.6651
SNU-201 CTRP2 7.5926 19.8459 0.5068 19.5508
GaMG CTRP2; CTRP1 7.7213 10.2872 5.2501 1.8887
GMS-10 CTRP2 7.7242 8.7002 5.8943 0.0964
SNU-1105 CTRP2 7.8356 8.9466 5.8489 0.1329
DK-MG CTRP2 7.8501 13.2255 3.9567 6.73
SNU-466 CTRP2 7.863 8.9069 5.8729 0.0963
U-87MG ATCC CTRP2 7.9841 9.6238 5.6584 0.442
CCF-STTG1 CTRP2 8.0032 9.0529 5.8728 0.0738
LN-18 CTRP2 8.0379 8.9973 5.9035 0.0439
SF295 CTRP2; CTRP1 8.2295 9.694 5.7315 0.2099
GOS-3 CTRP2 8.3193 11.6305 4.9896 2.2183
DBTRG-05MG CTRP2 8.337 9.7495 5.7522 0.1541
8-MG-BA CTRP2 8.911 15.8238 3.4242 7.3464
M059K CTRP2 13.3786 27.5405 0.7608 10.8722
TM-31 CTRP2 15.9185 35.4689 -1.3391 13.6082
⏷ Show the Full List of 39 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HEC-1-A CTRP2 5.2832 6.583 5.0767 6.9352
HEC-151 CTRP2; CTRP1 5.3487 6.572 5.1511 6.4666
HEC-6 CTRP2; CTRP1 5.6914 9.2491 4.2389 9.3614
JHUEM-1 CTRP2 5.7771 6.0992 5.7625 2.9374
MFE-319 CTRP2; CTRP1 5.8422 7.5653 5.2055 4.9987
MFE-296 CTRP2 5.9946 7.1501 5.5499 3.2247
ESS-1 CTRP2 6.1838 8.9457 4.8199 5.9048
JHUEM-2 CTRP2; CTRP1 6.7351 9.6192 4.9204 4.4953
JHUEM-3 CTRP2 6.7416 8.4127 5.5136 2.0484
EFE-184 CTRP2 6.7754 8.2274 5.6241 1.5621
KLE CTRP2; CTRP1 6.9645 10.4128 4.699 5.0434
AN3-CA CTRP2 7.107 11.4999 4.2699 6.5865
HEC-265 CTRP2; CTRP1 7.2536 8.9748 5.5694 1.2245
JHUEM-7 CTRP2 7.9788 9.6111 5.661 0.4384
RL95-2 CTRP2 7.9903 12.1435 4.5627 4.1532
HEC-251 CTRP2; CTRP1 8.0144 10.9273 5.1307 2.02
HEC-108 CTRP2; CTRP1 8.1224 9.5976 5.7249 0.2523
HEC-50B CTRP2 8.2328 9.9625 5.6342 0.3877
HEC-1-B CTRP2 8.2673 9.9881 5.6388 0.3649
HEC-59 CTRP2; CTRP1 8.3296 12.581 4.5692 3.7248
EN CTRP2 8.7066 10.2112 5.7259 0.1178
Ishikawa (Heraklio) 02 ER- CTRP2; CTRP1 8.0154 9.8098 5.5998 0.5671
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
UO-31 CTRP2 5.0968 6.384 4.9434 7.9765
OS-RC-2 CTRP2 5.3822 12.4593 2.3709 17.5848
TUHR14TKB CTRP2 5.4591 11.2181 3.0553 14.7407
VMRC-RCZ CTRP2 5.8042 7.2335 5.3301 4.5721
RCC10RGB CTRP2 5.9881 6.7044 5.7599 2.3711
KMRC-2 CTRP2 6.0101 6.9388 5.6677 2.7003
TUHR10TKB CTRP2 6.4648 7.561 5.7329 1.5648
KMRC-1 CTRP2 6.6934 10.4664 4.4696 6.4453
TUHR4TKB CTRP2 6.7034 8.2665 5.5578 1.9243
SNU-1272 CTRP2 7.0182 11.6845 4.1132 7.3776
VMRC-RCW CTRP2; CTRP1 7.3772 13.6681 3.4029 9.6814
786-O CTRP2 7.4211 11.9019 4.2988 5.9818
KMRC-3 CTRP2 8.0189 12.2208 4.5446 4.1876
ACHN CTRP2 8.1386 10.5446 5.3602 1.1591
769-P CTRP2 8.1907 9.5011 5.7854 0.1411
KMRC-20 CTRP2 8.437 16.4105 2.8249 10.2734
Caki-1 CTRP2 9.727 15.734 3.9608 4.4318
Caki-2 CTRP2 13.5663 25.5152 1.779 7.7573
⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 51 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SW48 CTRP2; CTRP1 4.59 9.1834 3.2243 16.0841
T84 CTRP2 4.9891 6.9579 4.6185 9.5146
LS513 CTRP2; CTRP1 5.087 6.506 4.8924 8.1946
NCI-H747 CTRP2 5.2781 7.3224 4.7655 8.1646
LS1034 CTRP2 5.388 6.5259 5.2103 6.1299
DLD-1 CTRP2; CTRP1 5.5726 6.6828 5.3456 5.0956
SNU-175 CTRP1 5.6581 6.4096 5.5433 8.7653
COLO 320 CTRP2; CTRP1 5.6665 7.6979 4.9754 6.3552
SW403 CTRP1 5.6772 7.7311 4.314 6.3238
SNU-C1 CTRP2 5.7102 6.3455 5.6222 3.6505
SNU-1040 CTRP1 5.7393 6.7457 5.4918 8.7199
C2BBe1 CTRP2; CTRP1 5.7709 6.6994 5.5446 3.7846
HCC-56 CTRP2 5.79 6.3883 5.6928 3.1546
SNU-81 CTRP1 5.8783 6.6231 5.6881 6.2775
SNU-C5 CTRP2; CTRP1 5.8822 7.4423 5.3028 4.5047
SW948 CTRP2; CTRP1 5.886 6.5117 5.7448 2.6895
SNU-C4 CTRP2; CTRP1 5.8896 6.9703 5.5381 3.5153
KM12 CTRP2; CTRP1 5.915 6.9195 5.5868 3.2552
SW480 CTRP1 5.917 8.057 5.032 11.8745
LoVo CTRP2; CTRP1 5.9408 10.2327 3.9698 9.9631
SW620 CTRP2; CTRP1 5.9671 8.6434 4.7851 6.4879
HCT 15 CTRP2 6.016 7.2364 5.527 3.2729
HCT 8 CTRP2; CTRP1 6.0417 6.9416 5.6956 2.5131
SNU-503 CTRP2 6.051 7.5606 5.3977 3.7399
CL-11 CTRP2 6.0884 7.9313 5.2457 4.3016
LS180 CTRP2; CTRP1 6.1542 7.8227 5.3563 3.703
LS411N CTRP2; CTRP1 6.209 7.5706 5.5285 2.8703
CW-2 CTRP2; CTRP1 6.2157 8.2922 5.1733 4.3539
GP2d CTRP2; CTRP1 6.2449 9.7364 4.4755 7.2372
SNU-61 CTRP2; CTRP1 6.2682 9.5982 4.5638 6.8208
CL-34 CTRP1 6.3002 7.2265 5.7745 3.561
COLO 678 CTRP2; CTRP1 6.3127 9.8251 4.4869 7.0601
SNU-1033 CTRP2 6.313 10.0243 4.3877 7.4768
NCI-H508 CTRP2; CTRP1 6.3487 7.6043 5.6244 2.2088
SK-CO-1 CTRP2; CTRP1 6.4704 8.8915 5.0792 4.2809
HCT 116 CTRP2; CTRP1 6.4779 8.1763 5.4398 2.7594
HT-55 CTRP2; CTRP1 6.5779 8.2872 5.4594 2.5149
LS123 CTRP2; CTRP1 6.6 9.0703 5.09 4.0132
RCM-1 [Human ESC] CTRP2; CTRP1 6.865 9.2541 5.1928 3.1693
CL-40 CTRP1 6.8818 8.87 5.3892 5.0273
RKO CTRP2; CTRP1 6.9783 8.5889 5.583 1.4704
HT115 CTRP2; CTRP1 7.1624 9.2712 5.3811 2.0202
SW1417 CTRP2 7.2307 11.1268 4.5412 5.281
MDST8 CTRP2; CTRP1 7.2632 8.4939 5.7801 0.5306
SNU-407 CTRP2 7.3427 10.1307 5.0936 2.9079
COLO205 CTRP2; CTRP1 7.5654 9.6147 5.4599 1.3079
HT-29 CTRP2; CTRP1 7.8 9.1243 5.7705 0.2777
SNU-C2A CTRP2; CTRP1 7.9076 12.1434 4.5102 4.4617
OUMS-23 CTRP2 8.0894 9.2255 5.8443 0.0899
COLO201 CTRP2 8.5316 14.0495 4.0144 5.5861
NCI-H716 CTRP2 11.2655 25.8962 0.194 14.9278
⏷ Show the Full List of 51 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 21 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Li-7 CTRP2 4.9827 7.6145 4.3344 10.6468
JHH-2 CTRP2 5.1178 7.6991 4.4339 9.9019
SNU-761 CTRP2 5.3494 7.1325 4.9221 7.3563
JHH-5 CTRP2 5.3973 7.1092 4.9815 6.9954
SNU-182 CTRP2 5.7274 6.5659 5.5563 3.8542
SNU-449 CTRP2; CTRP1 5.782 7.1786 5.3349 4.605
SNU-387 CTRP2 5.7928 6.9766 5.4405 4.148
JHH-6 CTRP2; CTRP1 5.8618 6.3281 5.7921 2.5736
PLC/PRF/5 CTRP2 5.9144 7.1175 5.4911 3.6507
SNU-398 CTRP2; CTRP1 5.9875 8.5197 4.8645 6.1114
SNU-423 CTRP2 6.2781 9.7644 4.4888 7.1176
JHH-4 CTRP2 6.2925 7.6603 5.552 2.6137
SNU-886 CTRP2 6.3222 7.895 5.4587 2.9516
Hep-G2 CTRP2; CTRP1 7.0796 8.8911 5.5057 1.6443
SNU-475 CTRP2 7.1146 9.1562 5.4048 1.9873
HLF CTRP2 7.4941 8.8648 5.7385 0.5002
Hep 3B2.1-7 CTRP2 7.9664 9.2431 5.7928 0.1842
JHH-1 CTRP2 7.9865 12.6896 4.3037 5.1666
HuH-6 CTRP2 8.4105 11.5742 5.0632 1.887
SK-HEP-1 CTRP2 9.858 19.6054 2.2535 10.348
HuH-1 CTRP2 14.4745 44.4865 -6.5553 24.4567
⏷ Show the Full List of 21 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 156 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H1581 CTRP2 3.6541 11.097 1.4082 25.2149
NCI-H1385 CTRP2 4.0109 5.0173 4.0034 14.708
NCI-H1963 CTRP1 4.2907 6.4115 4.057 25.5106
NCI-H82 CTRP1 4.472 5.5966 4.2736 12.0887
NCI-H1155 CTRP2 4.6121 6.9506 4.2197 12.0981
DMS 53 CTRP2 4.6874 6.3589 4.5053 10.8095
NCI-H1930 CTRP1 4.7143 7.9076 3.4284 17.9915
NCI-H1341 CTRP2 4.7388 6.9418 4.3584 11.2117
NCI-H446 CTRP2 4.766 6.9535 4.3829 11.0414
NCI-H1048 CTRP1 4.8352 6.1128 4.4176 8.8538
NCI-H1568 CTRP2; CTRP1 4.9018 7.5233 4.2911 11.0303
SCLC-21H CTRP1 4.902 6.244 4.7731 17.1911
NCI-H211 CTRP2 4.9029 7.7692 4.1844 11.4509
NCI-H810 CTRP2; CTRP1 5.0135 6.5423 4.8003 8.7534
COR-L88 CTRP1 5.0449 8.2593 3.5454 15.499
DMS 454 CTRP2 5.0521 7.4485 4.4784 9.8941
COR-L279 CTRP1 5.0685 7.1332 4.1277 10.3398
NCI-H2106 CTRP2 5.0758 6.4638 4.8945 8.2197
NCI-H1703 CTRP2 5.1027 9.8668 3.3927 14.1752
HCC44 CTRP2; CTRP1 5.1697 7.8231 4.4298 9.7871
NCI-H1573 CTRP1 5.1713 7.9907 3.7869 12.8993
DMS 273 CTRP2; CTRP1 5.2024 10.7595 3.0489 15.3356
NCI-H522 CTRP2; CTRP1 5.3111 7.9288 4.521 9.0673
NCI-H2087 CTRP2 5.334 6.9354 4.9907 7.1271
NCI-H2228 CTRP2 5.3467 9.4265 3.8354 11.8018
NCI-H1650 CTRP2 5.3681 6.698 5.1235 6.5175
HARA [Human squamous cell lung carcinoma] CTRP2; CTRP1 5.3746 8.3258 4.3947 9.4316
ChaGo-K-1 CTRP2; CTRP1 5.3811 7.9263 4.5908 8.6127
NCI-H358 CTRP2; CTRP1 5.4142 6.6604 5.1872 6.1443
NCI-H1563 CTRP2 5.4177 6.1153 5.3692 5.4558
NCI-H1944 CTRP2; CTRP1 5.4261 8.3269 4.4434 9.1096
Calu-3 CTRP2; CTRP1 5.4561 6.5238 5.2842 5.6558
HOP-62 CTRP2 5.4572 6.5305 5.2829 5.6577
NCI-H1666 CTRP2; CTRP1 5.466 6.93 5.1302 6.2264
RERF-LC-A1 CTRP2 5.4772 9.1067 4.113 10.3586
Lu-99 CTRP2; CTRP1 5.4808 6.0968 5.4419 5.0005
NCI-H23 CTRP2; CTRP1 5.4811 7.2712 4.9941 6.73
SK-MES-1 CTRP2 5.4853 7.99 4.6617 8.0726
NCI-H1975 CTRP1 5.4904 7.4109 4.3332 6.8054
COLO 668 CTRP2; CTRP1 5.5067 8.3342 4.5166 8.6202
EKVX CTRP2 5.5243 9.868 3.7819 11.6271
NCI-H2444 CTRP2 5.5306 6.1254 5.4897 4.6753
KNS-62 CTRP2; CTRP1 5.5514 7.2277 5.0845 6.1887
HCC95 CTRP2 5.571 6.4885 5.4206 4.8112
NCI-H596 CTRP1 5.5807 7.7672 4.86 15.0188
HCC1438 CTRP2 5.6074 6.0595 5.5864 4.0928
HCC1588 CTRP2 5.6129 6.1873 5.5643 4.1537
NCI-H1437 CTRP1 5.6176 7.5185 4.3749 5.9888
HCC15 CTRP2; CTRP1 5.6329 7.065 5.2406 5.3547
NCI-H889 CTRP2 5.6415 6.9154 5.3167 5.0274
HCC4006 CTRP2; CTRP1 5.6433 9.7665 3.9396 10.7136
NCI-H1694 CTRP2; CTRP1 5.6465 6.7748 5.3837 4.7481
NCI-H1105 CTRP2; CTRP1 5.6546 6.4987 5.5062 4.2487
LK2 CTRP2 5.6699 6.4104 5.5557 4.017
Lu-65 CTRP2; CTRP1 5.6721 7.7567 4.9524 6.4372
NCI-H2196 CTRP2 5.6779 6.8019 5.4042 4.5847
NCI-H226 CTRP2 5.6824 6.1748 5.6434 3.6559
NCI-H1915 CTRP2; CTRP1 5.7029 6.273 5.638 3.6131
SBC-5 CTRP2 5.7076 6.156 5.6754 3.4636
HOP-92 CTRP2 5.7077 7.2001 5.2522 5.1223
HCC2935 CTRP2; CTRP1 5.7087 6.9099 5.3872 4.5734
NCI-H1793 CTRP2; CTRP1 5.7409 6.5999 5.5564 3.8173
COR-L95 CTRP2 5.7477 7.143 5.3182 4.7559
DV-90 CTRP2; CTRP1 5.7515 6.4293 5.6362 3.4791
NCI-H647 CTRP2 5.7821 6.5266 5.63 3.4187
LUDLU-1 CTRP2 5.7989 7.4209 5.2349 4.9764
SHP-77 CTRP2; CTRP1 5.8017 10.4898 3.7206 11.288
T3M-10 CTRP2; CTRP1 5.8248 7.0571 5.434 4.0969
NCI-H2141 CTRP1 5.8324 9.045 4.4664 15.0771
PC-14 CTRP2 5.854 7.6222 5.1886 5.0425
EPLC-272H CTRP2; CTRP1 5.8553 7.1647 5.4121 4.1141
NCI-H1355 CTRP2; CTRP1 5.8615 6.7793 5.6001 3.331
LCLC-97TM1 CTRP1 5.8767 8.0275 4.3102 5.7183
COR-L51 CTRP1 5.8808 7.2542 5.393 7.737
NCI-H1373 CTRP2; CTRP1 5.9238 10.1065 4.0181 9.796
NCI-H2073 CTRP1 5.9313 7.7026 5.2201 10.1371
NCI-H2110 CTRP2; CTRP1 5.9406 7.5149 5.321 4.2986
NCI-H838 CTRP2 5.9708 6.9925 5.6047 3.0509
RERF-LC-KJ CTRP1 5.9731 8.5079 4.1451 6.8357
NCI-H841 CTRP2; CTRP1 5.9962 7.8231 5.2187 4.6064
NCI-H2122 CTRP2; CTRP1 5.997 7.9629 5.1499 4.8934
NCI-H2029 CTRP2; CTRP1 6.0458 8.0482 5.1503 4.7899
NCI-H2342 CTRP2; CTRP1 6.0571 7.858 5.255 4.3264
SW1271 CTRP2 6.0839 7.2713 5.5706 2.9449
HCC1195 CTRP2; CTRP1 6.113 7.3551 5.5544 2.9526
NCI-H1651 CTRP2 6.1461 9.3479 4.5871 6.9591
DMS 114 CTRP2 6.1574 7.8744 5.3332 3.7939
COLO 699 CTRP2; CTRP1 6.2081 8.4894 5.0683 4.8108
RERF-LC-MS CTRP2 6.2127 10.1946 4.2196 8.375
Calu-1 CTRP2 6.2247 7.3317 5.661 2.2818
NCI-H2170 CTRP2 6.2273 7.4375 5.6103 2.4904
HCC1359 CTRP1 6.2292 7.1143 5.7734 3.8499
NCI-H322 CTRP2 6.2307 7.077 5.7932 1.7131
NCI-H2081 CTRP2; CTRP1 6.2454 9.125 4.7815 5.9477
NCI-H1299 CTRP2; CTRP1 6.2649 9.4172 4.6516 6.4575
NCI-H520 CTRP2 6.2753 7.6444 5.5461 2.6704
NCI-H3255 CTRP1 6.3048 9.7064 4.5398 14.4339
HCC33 CTRP1 6.3144 9.42 3.9385 7.5429
NCI-H1395 CTRP2 6.4069 8.689 5.1301 4.1799
NCI-H1781 CTRP1 6.409 8.0348 5.4573 5.9966
HCC1171 CTRP2 6.4404 8.427 5.2868 3.4631
HCC2279 CTRP2 6.4576 8.3222 5.3521 3.1601
HCC1833 CTRP2; CTRP1 6.4859 8.0444 5.5109 2.4499
NCI-H1836 CTRP1 6.5113 10.8858 4.1179 16.9223
NCI-H1755 CTRP2; CTRP1 6.5237 9.1379 4.9982 4.5271
LXF 289 CTRP2; CTRP1 6.5259 11.8358 3.6554 10.1361
NCI-H1876 CTRP1 6.5726 10.6778 4.2703 15.5184
NCI-H2030 CTRP2; CTRP1 6.6102 8.6519 5.304 3.1064
NCI-H1869 CTRP2 6.705 17.2569 1.0931 19.3635
SK-LU-1 CTRP2; CTRP1 6.8271 8.4408 5.557 1.7585
NCI-H2286 CTRP2; CTRP1 6.8345 9.9922 4.8104 4.7903
NCI-H441 CTRP2; CTRP1 6.8639 8.5079 5.5492 1.7414
HCC827 CTRP2; CTRP1 6.8717 16.7964 1.4573 17.8468
CAL-12T CTRP2; CTRP1 6.8827 8.6984 5.4714 2.023
A-549 CTRP2; CTRP1 6.9421 10.0403 4.865 4.3948
NCI-H460 CTRP2; CTRP1 7.1207 8.4948 5.7071 0.8746
NCI-H2172 CTRP2; CTRP1 7.1737 9.6743 5.1996 2.7111
HCC366 CTRP2 7.2213 9.5992 5.2653 2.3936
Calu-6 CTRP2; CTRP1 7.2797 11.38 4.4527 5.5682
EBC-1 CTRP2; CTRP1 7.3938 11.7415 4.3574 5.7846
LOU-NH91 CTRP2 7.3944 11.0602 4.6864 4.4539
NCI-H661 CTRP2; CTRP1 7.4437 10.9644 4.7652 4.0704
IA-LM CTRP2 7.4441 8.9922 5.6625 0.7523
BEN CTRP2; CTRP1 7.4635 8.3005 5.9384 0.0929
MOR/CPR CTRP2 7.5171 8.3701 5.9338 0.0878
HCC2108 CTRP2; CTRP1 7.5473 11.6114 4.5257 4.8838
NCI-H2405 CTRP2; CTRP1 7.5518 11.4737 4.5945 4.6025
NCI-H1734 CTRP2 7.5797 9.9393 5.3248 1.7658
NCI-H2023 CTRP2; CTRP1 7.6814 10.5609 5.1036 2.4645
NCI-H2291 CTRP2 7.7367 10.0794 5.3502 1.5243
HCC78 CTRP2; CTRP1 7.7396 11.2188 4.8361 3.4093
LCLC-103H CTRP2; CTRP1 7.7408 10.5871 5.1268 2.3137
RERF-LC-Ad1 CTRP2 7.7646 8.8583 5.8536 0.143
NCI-H1184 CTRP2 7.8458 16.3412 2.4342 12.6586
VMRC-LCD CTRP2; CTRP1 7.8673 15.2967 2.9625 10.6238
NCI-H69 CTRP2 7.8963 13.0228 4.0854 6.152
NCI-H2126 CTRP2; CTRP1 7.9212 11.1024 4.9994 2.5856
NCI-H292 CTRP2 7.9382 9.6792 5.6167 0.5658
NCI-H196 CTRP2 7.9614 10.0718 5.4692 0.9596
NCI-H1792 CTRP2; CTRP1 7.9694 11.5594 4.82 3.1978
COR-L23 CTRP1 8.0007 9.3308 5.7743 0.4374
COR-L105 CTRP2 8.0015 15.0982 3.1556 9.6671
Sq-1 CTRP2; CTRP1 8.0019 9.3227 5.7777 0.1985
LC-1/sq-SF CTRP2; CTRP1 8.0626 9.8906 5.5891 0.5689
NCI-H526 CTRP2 8.1047 9.3978 5.7899 0.1539
NCI-H524 CTRP2 8.1241 11.0878 5.1206 1.951
NCI-H1339 CTRP2 8.2766 9.9455 5.6584 0.3232
NCI-H1435 CTRP2; CTRP1 8.2791 11.6088 4.9771 2.3
NCI-H1838 CTRP2 8.3286 10.245 5.5673 0.4916
RERF-LC-Ad2 CTRP2 8.3847 9.9032 5.7157 0.1942
NCI-H2085 CTRP2 8.9892 10.6921 5.6616 0.1414
NCI-H727 CTRP2; CTRP1 9.4222 16.709 3.3344 7.0347
NCI-H1623 CTRP2 9.7655 17.9565 2.9688 7.9409
NCI-H2009 CTRP2; CTRP1 11.5507 24.6724 0.9592 12.3639
NCI-H650 CTRP2; CTRP1 11.9633 31.2008 -1.8769 19.1793
Hs 888.Lu CTRP2 7.1672 9.6379 5.2126 2.6684
⏷ Show the Full List of 156 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Aska-SS CTRP2 6.2394 7.6438 5.5171 2.8601
Yamato-SS CTRP2 8.5804 17.3209 2.4841 11.3228
Rh41 CTRP2 4.4657 6.5543 4.2022 12.5863
A-204 CTRP2 4.7837 7.2817 4.2704 11.4276
Rh18 CTRP2 5.1387 5.9337 5.103 7.2734
KYM-1 CTRP2 5.2679 12.8765 2.0621 18.9882
GCT CTRP2 5.3608 6.1751 5.2925 5.9062
G-401 CTRP2; CTRP1 5.7154 10.3369 3.7209 11.4683
TE 617.T CTRP2 5.7314 6.298 5.6611 3.4432
TE 441.T CTRP2 5.7579 6.3208 5.6823 3.2868
MES-SA CTRP2 5.7783 6.393 5.6786 3.2419
HT-1080 CTRP2; CTRP1 5.9409 6.6476 5.74 2.5676
RD CTRP2 6.5788 8.1846 5.5102 2.3039
SK-UT-1 CTRP2 6.6931 9.4807 4.9573 4.4108
SK-LMS-1 CTRP2 6.7707 9.0622 5.2195 3.2025
BT-12 CTRP2 6.816 17.6223 1.0003 19.4496
RKN CTRP2; CTRP1 6.8489 9.5402 5.0422 3.8105
G-402 CTRP2 7.0947 10.43 4.7837 4.4956
TTC-709 CTRP2 7.388 9.7724 5.288 2.1077
Tm87-16 CTRP2 7.563 11.9115 4.3924 5.3965
BT-16 CTRP2 7.58 8.8629 5.7775 0.3561
SW982 CTRP2 7.7054 8.9801 5.7857 0.2834
Hs 729.T CTRP2 10.8103 19.4951 2.8963 6.9871
⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
P-STS CTRP2 8.0577 9.5762 5.707 0.3077
SYO-1 CTRP2 8.5805 10.2452 5.6679 0.2166
H-STS CTRP2 8.7042 26.9291 -2.1518 24.327
Cancer Drug Sensitivity Data Curated from 45 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
2004 CTRP2 8.4232 11.3432 5.1683 1.5367
A2780 CTRP2; CTRP1 4.8895 6.3619 4.7246 9.3997
ONCO-DG-1 CTRP2 5.2851 13.1741 1.9297 19.4309
SNU-119 CTRP2 5.368 6.9287 5.029 6.8852
OVCAR-5 CTRP2 5.4966 6.2 5.4341 4.9795
TOV-112D CTRP2 5.5227 9.9761 3.7271 11.8571
COV434 CTRP2; CTRP1 5.5264 8.6504 4.3817 9.1333
TYK-nu CTRP2; CTRP1 5.5721 6.8236 5.2858 5.3314
OC 314 CTRP2 5.6087 6.1409 5.5712 4.1423
Kuramochi CTRP2 5.6405 7.8512 4.8768 6.8226
OVKATE CTRP1 5.7274 6.3771 5.6296 6.687
OVMANA CTRP1 5.7763 7.0397 4.7125 2.605
RMUG-S CTRP1 5.8038 7.7871 5.0615 12.1494
COV318 CTRP1 5.8331 7.286 4.6335 3.1063
OAW42 CTRP2; CTRP1 5.844 6.3582 5.7621 2.7379
EFO-21 CTRP2; CTRP1 5.9206 7.5488 5.2861 4.4883
OV7 CTRP2; CTRP1 5.939 7.8251 5.1664 4.9479
JHOS-2 CTRP2 5.9542 6.6283 5.7621 2.4449
COV362 CTRP2; CTRP1 6.1839 7.214 5.6857 2.2566
COV644 CTRP2; CTRP1 6.197 7.07 5.7688 1.881
EFO-27 CTRP2; CTRP1 6.2051 8.289 5.166 4.405
HEY A8 CTRP2; CTRP1 6.2097 9.2696 4.6796 6.4457
OVCAR-4 CTRP2; CTRP1 6.2257 9.6946 4.4804 7.2533
OVK18 CTRP2; CTRP1 6.2719 10.0032 4.3644 7.6527
OVCAR-8 CTRP2; CTRP1 6.2918 9.2401 4.7622 5.9404
JHOS-4 CTRP1 6.2981 10.1198 3.5917 10.4076
TOV-21G CTRP2 6.3165 9.1335 4.8356 5.585
JHOM-1 CTRP2; CTRP1 6.3246 7.6554 5.58 2.4376
OV-90 CTRP2; CTRP1 6.4624 8.6099 5.213 3.7342
IGROV-1 CTRP2; CTRP1 6.5715 8.69 5.2564 3.3672
RMG-I CTRP2; CTRP1 6.9507 11.4533 4.1767 7.2272
OV56 CTRP2 6.9554 10.0798 4.8553 4.4143
JHOC-5 CTRP2; CTRP1 6.9975 8.4608 5.6529 1.1885
MCAS CTRP2 7.074 10.2175 4.8722 4.1654
FU-OV-1 CTRP2 7.1716 10.1115 4.9903 3.5464
Caov-3 CTRP2; CTRP1 7.3304 9.905 5.1913 2.5443
OVISE CTRP2 7.7385 8.7505 5.8819 0.1093
SNU-840 CTRP2; CTRP1 7.7624 13.7742 3.6301 8.1629
DOV13 CTRP2 8.3675 14.4831 3.7034 7.0018
ES2 CTRP2 8.3689 13.2601 4.2801 4.7713
SK-OV-3 CTRP2; CTRP1 8.527 11.3517 5.2165 1.3102
OVSAHO CTRP2 8.8447 10.6143 5.6361 0.2002
OAW28 CTRP2 8.9733 11.5757 5.3324 0.7321
OVTOKO CTRP2 10.333 19.3989 2.6524 8.3688
SNU-8 CTRP2 11.2859 24.5472 0.8475 13.0233
⏷ Show the Full List of 45 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MSTO-211H CTRP2; CTRP1 3.3691 7.7916 2.5695 21.8704
NCI-H28 CTRP2; CTRP1 5.4856 6.714 5.2413 5.7385
ACC-MESO-1 CTRP2 5.8777 6.6261 5.686 2.9445
NCI-H2452 CTRP2 6.5267 16.1737 1.4891 18.3971
JL-1 CTRP2 8.7046 10.3034 5.6934 0.1551
NCI-H2052 CTRP2; CTRP1 8.9654 15.4547 3.632 6.4937
IST-Mes1 CTRP2 12.6876 31.6652 -1.6085 17.6923
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LNCaP clone FGC CTRP2 5.0662 8.0273 4.2326 10.8421
DU145 CTRP2 5.8135 9.8404 4.0543 9.8729
PaCa-3 CTRP2; CTRP1 7.3802 11.8586 4.2911 6.0745
VCaP CTRP2 7.7027 14.195 3.3824 9.2401
22Rv1 CTRP2 8.0262 10.9589 5.1233 2.0343
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 CTRP2 5.68 6.4218 5.5624 3.9627
YD-15 CTRP2 7.8331 8.8317 5.8881 0.0841
Cancer Drug Sensitivity Data Curated from 33 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ECC10 CTRP2 0.6103 15.7569 -3.7697 43.7857
SNU-16 CTRP2 2.2055 9.1444 0.7954 31.3259
HGC-27 CTRP2 4.3933 5.8611 4.3105 12.4139
GSS CTRP2 4.7939 6.2838 4.6437 9.9832
NCC-StC-K140 CTRP2 5.1259 10.0554 3.3227 14.4057
NUGC-4 CTRP2; CTRP1 5.2696 8.5279 4.1971 10.4914
HuG1-N CTRP2 5.3736 11.6759 2.7518 16.1333
SNU-1 CTRP2 5.5614 6.5504 5.3868 4.9674
MKN1 CTRP2 5.5882 6.3418 5.4912 4.4958
SNU-601 CTRP2 5.6243 7.0067 5.2583 5.3053
Hs 746.T CTRP2 5.6583 6.1588 5.621 3.8108
ECC12 CTRP2 5.6594 6.0608 5.6422 3.7323
SNU-216 CTRP2 5.7598 6.8855 5.4498 4.1925
KE-39 CTRP2 5.9277 9.5944 4.2768 8.7036
IM95 CTRP2 6.0007 7.6481 5.3096 4.216
MKN74 CTRP2; CTRP1 6.2 9.1108 4.7509 6.1639
AGS CTRP2; CTRP1 6.5231 7.8056 5.6552 1.7939
MKN7 CTRP2; CTRP1 6.5285 9.5538 4.7952 5.3698
SNU-620 CTRP2 6.6805 10.288 4.5482 6.139
GSU CTRP2 6.9008 7.5319 5.9977 0.1655
SNU-5 CTRP2 7.3687 13.7062 3.3779 9.7954
SH-10-TC CTRP2; CTRP1 7.4338 10.0475 5.1894 2.4267
Fu97 CTRP2; CTRP1 7.5443 11.2462 4.6978 4.2018
MKN45 CTRP2 7.5782 8.5288 5.9005 0.1196
NCI-N87 CTRP2 7.896 11.8862 4.6233 4.0367
SNU-668 CTRP2 8.0009 9.2565 5.8011 0.1625
SNU-719 CTRP2 8.1304 10.0666 5.5502 0.6304
NUGC-3 CTRP2 8.1389 11.414 4.9848 2.411
23132/87 CTRP2 8.2309 14.3156 3.6921 7.2346
LMSU CTRP2 12.7084 25.9632 1.0796 10.6759
SNG-M CTRP2; CTRP1 5.7763 6.7332 5.5352 3.808
SNU-685 CTRP2 8.1477 10.5366 5.368 1.1288
SNU-1077 CTRP2 8.4173 12.5201 4.6489 3.3331
⏷ Show the Full List of 33 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 12 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TT CTRP2 5.4061 6.5838 5.2081 6.0872
SW579 CTRP2 5.5965 6.1979 5.5437 4.2785
CAL-62 CTRP2 5.7781 6.3836 5.6819 3.2299
CGTH-W-1 CTRP2 5.9117 7.5896 5.2579 4.6255
ML-1 [Human leukemia] CTRP2 6.1227 7.608 5.4366 3.4283
TT2609-C02 CTRP2 6.2187 8.4373 5.1033 4.6431
8505C CTRP2 6.4263 11.5574 3.714 10.0795
FTC-133 CTRP2 7.6791 13.1463 3.8764 7.3028
BHT-101 CTRP2 8.3368 9.7938 5.7365 0.1755
8305C CTRP2 8.7203 15.4389 3.482 7.3783
B-CPAP CTRP2 8.7973 19.7978 1.4326 14.6518
FTC-238 CTRP2 9.7347 19.3619 2.2881 10.3914
⏷ Show the Full List of 12 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 29 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
FaDu CTRP2 5.4357 6.519 5.264 5.7904
YD-8 CTRP2 5.464 6.8944 5.1434 6.1794
HSC-2 CTRP2; CTRP1 5.4912 9.4293 3.9677 10.9298
PE/CA-PJ49 CTRP2 5.5629 6.0656 5.5373 4.4059
PE/CA-PJ34 (clone C12) CTRP2 5.7117 7.0938 5.3059 4.8942
CAL-33 CTRP2 5.7174 7.5028 5.1178 5.6495
SCC-4 CTRP2 5.7422 6.3038 5.671 3.3749
PE/CA-PJ15 CTRP2 5.8158 7.2453 5.3355 4.5223
HSC-4 CTRP2 5.913 7.4417 5.3317 4.3151
PE/CA-PJ41 (clone D2) CTRP2 6.1307 8.0869 5.2043 4.39
SCC-25 CTRP2 6.1808 8.9145 4.833 5.8557
BICR 16 CTRP2 6.3905 8.3401 5.291 3.5335
BICR 22 CTRP2 6.7994 8.5196 5.5013 2.017
SCC-9 CTRP2; CTRP1 6.9795 8.8046 5.4838 1.8494
Detroit 562 CTRP2 7.5681 10.1292 5.2327 2.1123
BICR 6 CTRP2 7.7071 8.9986 5.7795 0.2957
BICR 18 CTRP2 7.7548 11.0754 4.912 3.1008
HSC-3 CTRP2 7.8272 9.5798 5.6058 0.6584
SNU-899 CTRP2 7.9885 9.2485 5.7992 0.1683
SNU-1214 CTRP2 8.0899 11.4568 4.9377 2.6306
YD-10B CTRP2 8.1344 15.3727 3.1161 9.6178
BHY CTRP2 8.3623 10.7005 5.4037 0.8827
BICR 56 CTRP2 8.3795 9.6286 5.8092 0.0826
BICR 31 CTRP2 8.5935 13.7024 4.2142 4.7508
SNU-1066 CTRP2 8.6602 10.1428 5.7329 0.1177
SNU-1041 CTRP2 8.856 10.7938 5.5765 0.286
SNU-46 CTRP2 8.9799 10.7037 5.6543 0.1511
CAL-27 CTRP2 10.7844 24.0836 0.7374 13.994
SNU-1076 CTRP2 12.95 24.1302 2.0474 7.5388
⏷ Show the Full List of 29 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
253J CTRP2 4.8439 5.8796 4.7945 9.2891
U-BLC1 CTRP2 5.2248 6.9895 4.8539 7.9563
JMSU-1 CTRP2 5.3507 8.4416 4.3163 9.81
TCCSUP CTRP2 5.3959 6.284 5.3002 5.7717
KMBC-2 CTRP2; CTRP1 5.3978 7.9695 4.5867 8.5889
HT-1197 CTRP2 5.4451 8.8346 4.2159 10.005
BC-3C CTRP2 5.4973 6.1425 5.4494 4.9226
CAL-29 CTRP2 5.746 6.3939 5.6436 3.4664
BFTC-905 CTRP2 5.7569 6.3365 5.6759 3.3136
253J-BV CTRP2 5.8253 7.2273 5.3533 4.4269
5637 CTRP2; CTRP1 6.0712 8.9337 4.7305 6.5045
HT-1376 CTRP2; CTRP1 6.1555 11.1705 3.6838 10.7249
J82 CTRP2 6.293 7.4588 5.6529 2.1882
SW1710 CTRP2 6.5992 8.5613 5.3405 2.9731
UM-UC-1 CTRP2 6.6037 11.9187 3.6764 9.9067
KU-19-19 CTRP2 7.1001 9.3468 5.3064 2.3874
VM-CUB-1 CTRP2 7.5951 11.1236 4.7889 3.7752
UM-UC-3 CTRP2; CTRP1 7.7865 11.1623 4.8913 3.1418
639V CTRP2 7.83 8.9222 5.8555 0.125
RT-4 CTRP2; CTRP1 7.9634 12.7084 4.2797 5.2915
SCaBER CTRP2 8.0167 10.5187 5.3093 1.415
RT-112 CTRP2 8.8023 10.536 5.6479 0.1935
T24 CTRP2 9.4657 19.842 1.8789 12.1683
⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HeLa CTRP2 7.5246 8.5745 5.8633 0.1973

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Tacrolimus
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Azathioprine DMMZSXQ Moderate Additive immunosuppressive effects by the combination of Tacrolimus and Azathioprine. Transplant rejection [NE84] [21]
Coadministration of a Drug Treating the Disease Different from Tacrolimus (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Decreased renal excretion of Tacrolimus caused by Remdesivir mediated nephrotoxicity. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [21]
Sodium bicarbonate DMMU6BJ Moderate Decreased absorption of Tacrolimus due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [22]
Repaglinide DM5SXUV Moderate Increased plasma concentrations of Tacrolimus and Repaglinide due to competitive inhibition of the same metabolic pathway. Acute diabete complication [5A2Y] [22]
Pioglitazone DMKJ485 Moderate Increased plasma concentrations of Tacrolimus and Pioglitazone due to competitive inhibition of the same metabolic pathway. Acute diabete complication [5A2Y] [22]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Tacrolimus and Ivosidenib. Acute myeloid leukaemia [2A60] [23]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Midostaurin. Acute myeloid leukaemia [2A60] [24]
Idarubicin DMM0XGL Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Idarubicin. Acute myeloid leukaemia [2A60] [25]
Arn-509 DMT81LZ Major Increased metabolism of Tacrolimus caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [26]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Gilteritinib. Acute myeloid leukaemia [2A60] [27]
Oliceridine DM6MDCF Moderate Increased plasma concentrations of Tacrolimus and Oliceridine due to competitive inhibition of the same metabolic pathway. Acute pain [MG31] [22]
Framycetin DMF8DNE Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Framycetin. Alcoholic liver disease [DB94] [22]
Metronidazole DMTIVEN Moderate Decreased metabolism of Tacrolimus caused by Metronidazole mediated inhibition of CYP450 enzyme. Amoebiasis [1A36] [28]
Inotersen DMJ93CT Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Inotersen. Amyloidosis [5D00] [29]
Siltuximab DMGEATB Moderate Additive immunosuppressive effects by the combination of Tacrolimus and Siltuximab. Anemia [3A00-3A9Z] [29]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Ivabradine. Angina pectoris [BA40] [29]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Tacrolimus and Bepridil. Angina pectoris [BA40] [24]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Tacrolimus and Dronedarone. Angina pectoris [BA40] [24]
Nifedipine DMSVOZT Moderate Decreased metabolism of Tacrolimus caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [30]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Tacrolimus and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [31]
Cilostazol DMZMSCT Moderate Increased plasma concentrations of Tacrolimus and Cilostazol due to competitive inhibition of the same metabolic pathway. Arterial occlusive disease [BD40] [22]
Posaconazole DMUL5EW Major Decreased metabolism of Tacrolimus caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [32]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Levalbuterol. Asthma [CA23] [33]
Terbutaline DMD4381 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Terbutaline. Asthma [CA23] [34]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Pirbuterol. Asthma [CA23] [34]
Budesonide DMJIBAW Moderate Increased plasma concentrations of Tacrolimus and Budesonide due to competitive inhibition of the same metabolic pathway. Asthma [CA23] [22]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Salbutamol. Asthma [CA23] [33]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Tacrolimus and Roflumilast. Asthma [CA23] [29]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Formoterol. Asthma [CA23] [34]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [29]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Desipramine. Attention deficit hyperactivity disorder [6A05] [24]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Ofloxacin. Bacterial infection [1A00-1C4Z] [35]
Kanamycin DM2DMPO Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Kanamycin. Bacterial infection [1A00-1C4Z] [22]
Tindamax DM3OWT4 Moderate Decreased metabolism of Tacrolimus caused by Tindamax mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [28]
Dalfopristin DM4LTKV Major Decreased metabolism of Tacrolimus caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [36]
Sulfamethoxazole DMB08GE Moderate Increased risk of nephrotoxicity by the combination of Tacrolimus and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [21]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Tacrolimus and Sparfloxacin. Bacterial infection [1A00-1C4Z] [35]
Streptomycin DME1LQN Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Streptomycin. Bacterial infection [1A00-1C4Z] [22]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Gemifloxacin. Bacterial infection [1A00-1C4Z] [35]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Norfloxacin. Bacterial infection [1A00-1C4Z] [35]
Rabeprazole DMMZXIW Moderate Increased risk of hypomagnesemia by the combination of Tacrolimus and Rabeprazole. Bacterial infection [1A00-1C4Z] [37]
Netilmicin DMRD1QK Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Netilmicin. Bacterial infection [1A00-1C4Z] [22]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Levofloxacin. Bacterial infection [1A00-1C4Z] [35]
Troleandomycin DMUZNIG Major Increased risk of prolong QT interval by the combination of Tacrolimus and Troleandomycin. Bacterial infection [1A00-1C4Z] [38]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Lomefloxacin. Bacterial infection [1A00-1C4Z] [24]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Retigabine. Behcet disease [4A62] [24]
Erdafitinib DMI782S Moderate Increased metabolism of Tacrolimus caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [39]
Etidronic acid DM1XHYJ Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Etidronic acid. Bone paget disease [FB85] [22]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Tacrolimus caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [21]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Eribulin. Breast cancer [2C60-2C6Y] [24]
Talazoparib DM1KS78 Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [40]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Lapatinib. Breast cancer [2C60-2C6Y] [24]
Exemestane DM9HPW3 Moderate Increased plasma concentrations of Tacrolimus and Exemestane due to competitive inhibition of the same metabolic pathway. Breast cancer [2C60-2C6Y] [22]
Tucatinib DMBESUA Major Decreased metabolism of Tacrolimus caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [32]
Palbociclib DMD7L94 Moderate Decreased metabolism of Tacrolimus caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [21]
Letrozole DMH07Y3 Moderate Increased plasma concentrations of Tacrolimus and Letrozole due to competitive inhibition of the same metabolic pathway. Breast cancer [2C60-2C6Y] [22]
Quinestrol DMJ6H1Z Moderate Increased plasma concentrations of Tacrolimus and Quinestrol due to competitive inhibition of the same metabolic pathway. Breast cancer [2C60-2C6Y] [22]
Cabazitaxel DMPAZHC Moderate Increased plasma concentrations of Tacrolimus and Cabazitaxel due to competitive inhibition of the same metabolic pathway. Breast cancer [2C60-2C6Y] [22]
Bosutinib DMTI8YE Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Bosutinib. Breast cancer [2C60-2C6Y] [29]
Atorvastatin DMF28YC Moderate Increased plasma concentrations of Tacrolimus and Atorvastatin due to competitive inhibition of the same metabolic pathway. Cardiovascular disease [BA00-BE2Z] [41]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Iodipamide. Cholelithiasis [DC11] [42]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [43]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Olodaterol. Chronic obstructive pulmonary disease [CA22] [34]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Vilanterol. Chronic obstructive pulmonary disease [CA22] [33]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Salmeterol. Chronic obstructive pulmonary disease [CA22] [34]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Indacaterol. Chronic obstructive pulmonary disease [CA22] [34]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Arformoterol. Chronic obstructive pulmonary disease [CA22] [34]
Dihydrocodeine DMB0FWL Moderate Increased plasma concentrations of Tacrolimus and Dihydrocodeine due to competitive inhibition of the same metabolic pathway. Chronic pain [MG30] [22]
Ketoprofen DMRKXPT Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Ketoprofen. Chronic pain [MG30] [22]
Fidaxomicin DMFP6MV Minor Decreased clearance of Tacrolimus due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [44]
Isoproterenol DMK7MEY Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Isoproterenol. Conduction disorder [BC63] [33]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Tacrolimus and Drospirenone. Contraceptive management [QA21] [45]
Levonorgestrel DM1DP7T Moderate Increased plasma concentrations of Tacrolimus and Levonorgestrel due to competitive inhibition of the same metabolic pathway. Contraceptive management [QA21] [22]
Levobupivacaine DM783CH Moderate Increased plasma concentrations of Tacrolimus and Levobupivacaine due to competitive inhibition of the same metabolic pathway. Corneal disease [9A76-9A78] [22]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Sevoflurane. Corneal disease [9A76-9A78] [24]
Methoxyflurane DML0RAE Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Methoxyflurane. Corneal disease [9A76-9A78] [22]
Cocaine DMSOX7I Moderate Increased plasma concentrations of Tacrolimus and Cocaine due to competitive inhibition of the same metabolic pathway. Corneal disease [9A76-9A78] [22]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Probucol. Coronary atherosclerosis [BA80] [24]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Tacrolimus and Pasireotide. Cushing syndrome [5A70] [24]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Osilodrostat. Cushing syndrome [5A70] [29]
Lumacaftor DMCLWDJ Major Increased metabolism of Tacrolimus caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [21]
Ivacaftor DMZC1HS Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [46]
MK-8228 DMOB58Q Major Decreased metabolism of Tacrolimus caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [47]
Rivaroxaban DMQMBZ1 Moderate Decreased metabolism of Tacrolimus caused by Rivaroxaban mediated inhibition of CYP450 enzyme. Deep vein thrombosis [BD71] [48]
Sertraline DM0FB1J Moderate Increased plasma concentrations of Tacrolimus and Sertraline due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [22]
Cyclobenzaprine DM1YBRM Moderate Increased plasma concentrations of Tacrolimus and Cyclobenzaprine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [22]
Nefazodone DM4ZS8M Major Decreased metabolism of Tacrolimus caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [32]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Tacrolimus and Escitalopram. Depression [6A70-6A7Z] [24]
OPC-34712 DMHG57U Moderate Increased plasma concentrations of Tacrolimus and OPC-34712 due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [22]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Clomipramine. Depression [6A70-6A7Z] [24]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Doxepin. Depression [6A70-6A7Z] [24]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Maprotiline. Depression [6A70-6A7Z] [24]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [24]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Deutetrabenazine. Dystonic disorder [8A02] [49]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Ingrezza. Dystonic disorder [8A02] [50]
Zonisamide DM0DTF7 Moderate Increased plasma concentrations of Tacrolimus and Zonisamide due to competitive inhibition of the same metabolic pathway. Epilepsy/seizure [8A61-8A6Z] [22]
Felbamate DM1V5ZS Moderate Increased metabolism of Tacrolimus caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [21]
Cenobamate DM8KLU9 Moderate Increased metabolism of Tacrolimus caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [21]
Tiagabine DMKSQG0 Moderate Increased plasma concentrations of Tacrolimus and Tiagabine due to competitive inhibition of the same metabolic pathway. Epilepsy/seizure [8A61-8A6Z] [22]
Stiripentol DMMSDOY Moderate Decreased metabolism of Tacrolimus caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [51]
Fosphenytoin DMOX3LB Major Accelerated clearance of Tacrolimus due to the transporter induction by Fosphenytoin. Epilepsy/seizure [8A61-8A6Z] [26]
Phenobarbital DMXZOCG Major Increased metabolism of Tacrolimus caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Tazemetostat DMWP1BH Moderate Increased metabolism of Tacrolimus caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [21]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Solifenacin. Functional bladder disorder [GC50] [24]
Tolterodine DMSHPW8 Moderate Increased plasma concentrations of Tacrolimus and Tolterodine due to competitive inhibition of the same metabolic pathway. Functional bladder disorder [GC50] [22]
Itraconazole DMCR1MV Major Decreased metabolism of Tacrolimus caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [32]
Miconazole DMPMYE8 Moderate Decreased metabolism of Tacrolimus caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [52]
Ketoconazole DMPZI3Q Major Decreased metabolism of Tacrolimus caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [32]
Ripretinib DM958QB Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Ripretinib. Gastrointestinal stromal tumour [2B5B] [21]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Sunitinib. Gastrointestinal stromal tumour [2B5B] [24]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Tacrolimus caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [21]
Digitoxin DMWVIGP Moderate Increased plasma concentrations of Tacrolimus and Digitoxin due to competitive inhibition of the same metabolic pathway. Heart failure [BD10-BD1Z] [22]
Boceprevir DMBSHMF Major Decreased metabolism of Tacrolimus caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [21]
Simeprevir DMLUA9D Moderate Decreased metabolism of Tacrolimus caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [21]
Telaprevir DMMRV29 Major Decreased clearance of Tacrolimus due to the transporter inhibition by Telaprevir. Hepatitis virus infection [1E50-1E51] [21]
177Lu-DOTATATE DMT8GVU Major Increased risk of nephrotoxicity by the combination of Tacrolimus and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [22]
Rifampin DMA8J1G Major Accelerated clearance of Tacrolimus due to the transporter induction by Rifampin. HIV-infected patients with tuberculosis [1B10-1B14] [26]
Rifapentine DMCHV4I Major Increased metabolism of Tacrolimus caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [26]
Brentuximab vedotin DMWLC57 Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Brentuximab vedotin. Hodgkin lymphoma [2B30] [53]
MK-1439 DM215WE Minor Increased metabolism of Tacrolimus caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [29]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Tacrolimus caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [54]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [55]
Cobicistat DM6L4H2 Major Decreased metabolism of Tacrolimus caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [32]
Tipranavir DM8HJX6 Moderate Accelerated clearance of Tacrolimus due to the transporter induction by Tipranavir. Human immunodeficiency virus disease [1C60-1C62] [56]
Etravirine DMGV8QU Moderate Increased metabolism of Tacrolimus caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [21]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [24]
Darunavir DMN3GCH Major Decreased metabolism of Tacrolimus caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [54]
Atazanavir DMSYRBX Major Decreased metabolism of Tacrolimus caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [54]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Tacrolimus and Teriflunomide. Hyper-lipoproteinaemia [5C80] [57]
Eprosartan DM07K2I Moderate Increased risk of hyperkalemia by the combination of Tacrolimus and Eprosartan. Hypertension [BA00-BA04] [58]
Aliskiren DM1BV7W Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [24]
Captopril DM458UM Moderate Increased risk of hyperkalemia by the combination of Tacrolimus and Captopril. Hypertension [BA00-BA04] [58]
TAK-491 DMCF6SX Moderate Increased risk of hyperkalemia by the combination of Tacrolimus and TAK-491. Hypertension [BA00-BA04] [58]
Felodipine DMOSW35 Moderate Increased plasma concentrations of Tacrolimus and Felodipine due to competitive inhibition of the same metabolic pathway. Hypertension [BA00-BA04] [22]
Quinapril DMR8H31 Moderate Decreased absorption of Tacrolimus due to formation of complexes caused by Quinapril. Hypertension [BA00-BA04] [29]
Telmisartan DMS3GX2 Moderate Increased risk of hyperkalemia by the combination of Tacrolimus and Telmisartan. Hypertension [BA00-BA04] [58]
Irbesartan DMTP1DC Moderate Increased risk of hyperkalemia by the combination of Tacrolimus and Irbesartan. Hypertension [BA00-BA04] [58]
Conivaptan DM1V329 Major Decreased metabolism of Tacrolimus caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [32]
Givosiran DM5PFIJ Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [22]
Lesinurad DMUR64T Moderate Increased metabolism of Tacrolimus caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [59]
Balsalazide DM7I1T9 Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Balsalazide. Indeterminate colitis [DD72] [22]
Meclofenamic acid DM05FXR Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [22]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Tacrolimus caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [21]
Amobarbital DM0GQ8N Moderate Increased metabolism of Tacrolimus caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [21]
Triazolam DMETYK5 Moderate Increased plasma concentrations of Tacrolimus and Triazolam due to competitive inhibition of the same metabolic pathway. Insomnia [7A00-7A0Z] [22]
Zaleplon DMGFWSM Moderate Increased plasma concentrations of Tacrolimus and Zaleplon due to competitive inhibition of the same metabolic pathway. Insomnia [7A00-7A0Z] [22]
ITI-007 DMUQ1DO Moderate Increased plasma concentrations of Tacrolimus and ITI-007 due to competitive inhibition of the same metabolic pathway. Insomnia [7A00-7A0Z] [22]
Quazepam DMY4D87 Moderate Increased plasma concentrations of Tacrolimus and Quazepam due to competitive inhibition of the same metabolic pathway. Insomnia [7A00-7A0Z] [22]
Estazolam DMZGXUM Moderate Increased plasma concentrations of Tacrolimus and Estazolam due to competitive inhibition of the same metabolic pathway. Insomnia [7A00-7A0Z] [22]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Polyethylene glycol. Irritable bowel syndrome [DD91] [29]
Naloxegol DML0B41 Minor Decreased clearance of Tacrolimus due to the transporter inhibition by Naloxegol. Large intestine motility disorder [DB32] [60]
Glycerol phenylbutyrate DMDGRQO Moderate Increased metabolism of Tacrolimus caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme. Liver disease [DB90-DB9Z] [29]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Tacrolimus and Denosumab. Low bone mass disorder [FB83] [61]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Tacrolimus and Crizotinib. Lung cancer [2C25] [62]
Brigatinib DM7W94S Moderate Increased metabolism of Tacrolimus caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [21]
Ceritinib DMB920Z Major Decreased metabolism of Tacrolimus caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [32]
PF-06463922 DMKM7EW Moderate Increased metabolism of Tacrolimus caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [63]
Osimertinib DMRJLAT Moderate Decreased metabolism of Tacrolimus caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [29]
Capmatinib DMYCXKL Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [64]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Tacrolimus and Selpercatinib. Lung cancer [2C25] [29]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Tacrolimus and Lumefantrine. Malaria [1F40-1F45] [21]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Tacrolimus and Halofantrine. Malaria [1F40-1F45] [65]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Primaquine. Malaria [1F40-1F45] [24]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [29]
Idelalisib DM602WT Major Decreased metabolism of Tacrolimus caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [32]
GDC-0199 DMH0QKA Major Decreased clearance of Tacrolimus due to the transporter inhibition by GDC-0199. Mature B-cell leukaemia [2A82] [21]
Moxetumomab pasudotox DMN63DZ Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Moxetumomab pasudotox. Mature B-cell leukaemia [2A82] [22]
IPI-145 DMWA24P Moderate Decreased metabolism of Tacrolimus caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [21]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Arsenic trioxide. Mature B-cell lymphoma [2A85] [66]
Blinatumomab DMGECIJ Moderate Decreased metabolism of Tacrolimus caused by Blinatumomab mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [67]
Ibrutinib DMHZCPO Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Ibrutinib. Mature B-cell lymphoma [2A85] [29]
Arry-162 DM1P6FR Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Arry-162. Melanoma [2C30] [21]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Tacrolimus and Vemurafenib. Melanoma [2C30] [24]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and LGX818. Melanoma [2C30] [68]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Tacrolimus caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [21]
Ethinyl estradiol DMODJ40 Moderate Increased plasma concentrations of Tacrolimus and Ethinyl estradiol due to competitive inhibition of the same metabolic pathway. Menopausal disorder [GA30] [22]
Danazol DML8KTN Moderate Decreased metabolism of Tacrolimus caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [22]
Almogran DM7I64Z Moderate Increased plasma concentrations of Tacrolimus and Almogran due to competitive inhibition of the same metabolic pathway. Migraine [8A80] [22]
Rimegepant DMHOAUG Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Rimegepant. Migraine [8A80] [69]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Exjade. Mineral absorption/transport disorder [5C64] [70]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Tacrolimus due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [24]
Gallium nitrate DMF9O6B Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Gallium nitrate. Mineral excesses [5B91] [22]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Tacrolimus and Panobinostat. Multiple myeloma [2A83] [71]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Thalidomide. Multiple myeloma [2A83] [21]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Tacrolimus and Tecfidera. Multiple sclerosis [8A40] [72]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Tacrolimus and Siponimod. Multiple sclerosis [8A40] [21]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Tacrolimus and Fingolimod. Multiple sclerosis [8A40] [73]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Tacrolimus and Ocrelizumab. Multiple sclerosis [8A40] [74]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Tacrolimus and Ozanimod. Multiple sclerosis [8A40] [29]
Deflazacort DMV0RNS Moderate Increased plasma concentrations of Tacrolimus and Deflazacort due to competitive inhibition of the same metabolic pathway. Muscular dystrophy [8C70] [22]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Romidepsin. Mycosis fungoides [2B01] [24]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Tacrolimus caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [21]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Tacrolimus and Nilotinib. Myeloproliferative neoplasm [2A20] [24]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Dasatinib. Myeloproliferative neoplasm [2A20] [75]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Tacrolimus and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [76]
Busulfan DMXYJ9C Moderate Increased plasma concentrations of Tacrolimus and Busulfan due to competitive inhibition of the same metabolic pathway. Myeloproliferative neoplasm [2A20] [22]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Promethazine. Nausea/vomiting [MD90] [24]
Netupitant DMEKAYI Moderate Decreased metabolism of Tacrolimus caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [21]
Metoclopramide DMFA5MY Moderate Altered absorption of Tacrolimus due to GI dynamics variation caused by Metoclopramide. Nausea/vomiting [MD90] [77]
Granisetron DMIUW25 Moderate Increased plasma concentrations of Tacrolimus and Granisetron due to competitive inhibition of the same metabolic pathway. Nausea/vomiting [MD90] [22]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Ondansetron. Nausea/vomiting [MD90] [24]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Entrectinib. Non-small cell lung cancer [2C25] [21]
Sibutramine DMFJTDI Moderate Increased plasma concentrations of Tacrolimus and Sibutramine due to competitive inhibition of the same metabolic pathway. Obesity [5B80-5B81] [22]
Benzphetamine DMIJATC Moderate Increased plasma concentrations of Tacrolimus and Benzphetamine due to competitive inhibition of the same metabolic pathway. Obesity [5B80-5B81] [22]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Tacrolimus and Levomethadyl Acetate. Opioid use disorder [6C43] [29]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Lofexidine. Opioid use disorder [6C43] [24]
S-297995 DM26IH8 Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by S-297995. Opioid use disorder [6C43] [29]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Rucaparib. Ovarian cancer [2C73] [24]
Ibuprofen DM8VCBE Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Ibuprofen. Pain [MG30-MG3Z] [22]
Buprenorphine DMPRI8G Moderate Increased plasma concentrations of Tacrolimus and Buprenorphine due to competitive inhibition of the same metabolic pathway. Pain [MG30-MG3Z] [22]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Triclabendazole. Parasitic worm infestation [1F90] [24]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Pimavanserin. Parkinsonism [8A00] [78]
Bromocriptine DMVE3TK Moderate Decreased metabolism of Tacrolimus caused by Bromocriptine mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [21]
Abametapir DM2RX0I Moderate Decreased metabolism of Tacrolimus caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [79]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Famotidine. Peptic ulcer [DA61] [21]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Tacrolimus and Macimorelin. Pituitary gland disorder [5A60-5A61] [80]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Tacrolimus and Lefamulin. Pneumonia [CA40] [81]
Bromfenac DMKB79O Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Bromfenac. Postoperative inflammation [1A00-CA43] [22]
Ergonovine DM0VEC1 Moderate Increased plasma concentrations of Tacrolimus and Ergonovine due to competitive inhibition of the same metabolic pathway. Postpartum haemorrhage [JA43] [22]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Tacrolimus caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [32]
Ritodrine DM4V6RL Moderate Increased risk of ventricular arrhythmias by the combination of Tacrolimus and Ritodrine. Preterm labour/delivery [JB00] [34]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Degarelix. Prostate cancer [2C82] [29]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and ABIRATERONE. Prostate cancer [2C82] [29]
Enzalutamide DMGL19D Major Increased metabolism of Tacrolimus caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [26]
Relugolix DMK7IWL Major Decreased clearance of Tacrolimus due to the transporter inhibition by Relugolix. Prostate cancer [2C82] [82]
Bicalutamide DMZMSPF Moderate Decreased metabolism of Tacrolimus caused by Bicalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [21]
Silodosin DMJSBT6 Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Silodosin. Prostate hyperplasia [GA90] [83]
Dutasteride DMQ4TJK Moderate Increased plasma concentrations of Tacrolimus and Dutasteride due to competitive inhibition of the same metabolic pathway. Prostate hyperplasia [GA90] [22]
Finasteride DMWV3TZ Moderate Increased plasma concentrations of Tacrolimus and Finasteride due to competitive inhibition of the same metabolic pathway. Prostate hyperplasia [GA90] [22]
Ustekinumab DMHTYK3 Moderate Additive myelosuppressive effects by the combination of Tacrolimus and Ustekinumab. Psoriasis [EA90] [29]
Tildrakizumab DMLW9HG Moderate Additive myelosuppressive effects by the combination of Tacrolimus and Tildrakizumab. Psoriasis [EA90] [29]
Risankizumab DMM32GT Moderate Additive immunosuppressive effects by the combination of Tacrolimus and Risankizumab. Psoriasis [EA90] [29]
Ixekizumab DMXW92T Moderate Additive myelosuppressive effects by the combination of Tacrolimus and Ixekizumab. Psoriasis [EA90] [29]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Levomepromazine. Psychotic disorder [6A20-6A25] [24]
Riociguat DMXBLMP Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Riociguat. Pulmonary hypertension [BB01] [21]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Tacrolimus and Gatifloxacin. Respiratory infection [CA07-CA4Z] [84]
Colistimethate DMZ9BMU Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Colistimethate. Respiratory infection [CA07-CA4Z] [22]
Salsalate DM13P4C Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Salsalate. Rheumatoid arthritis [FA20] [22]
Tocilizumab DM7J6OR Moderate Additive immunosuppressive effects by the combination of Tacrolimus and Tocilizumab. Rheumatoid arthritis [FA20] [29]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Tacrolimus and Canakinumab. Rheumatoid arthritis [FA20] [29]
Rilonacept DMGLUQS Moderate Additive myelosuppressive effects by the combination of Tacrolimus and Rilonacept. Rheumatoid arthritis [FA20] [29]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Tacrolimus and Golimumab. Rheumatoid arthritis [FA20] [85]
Dexamethasone DMMWZET Moderate Increased metabolism of Tacrolimus caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [21]
Sarilumab DMOGNXY Moderate Additive myelosuppressive effects by the combination of Tacrolimus and Sarilumab. Rheumatoid arthritis [FA20] [29]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Tacrolimus and Leflunomide. Rheumatoid arthritis [FA20] [57]
Quetiapine DM1N62C Moderate Increased plasma concentrations of Tacrolimus and Quetiapine due to competitive inhibition of the same metabolic pathway. Schizophrenia [6A20] [22]
Aripiprazole DM3NUMH Moderate Increased plasma concentrations of Tacrolimus and Aripiprazole due to competitive inhibition of the same metabolic pathway. Schizophrenia [6A20] [22]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Tacrolimus and Iloperidone. Schizophrenia [6A20] [24]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Paliperidone. Schizophrenia [6A20] [24]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Tacrolimus and Amisulpride. Schizophrenia [6A20] [86]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Asenapine. Schizophrenia [6A20] [24]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Tacrolimus and Pimozide. Schizophrenia [6A20] [29]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Tacrolimus when combined with Anthrax vaccine. Sepsis [1G40-1G41] [87]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Tacrolimus caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [21]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Tacrolimus caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [29]
Larotrectinib DM26CQR Moderate Decreased metabolism of Tacrolimus caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [21]
Methylprednisolone DM4BDON Moderate Increased plasma concentrations of Tacrolimus and Methylprednisolone due to competitive inhibition of the same metabolic pathway. Solid tumour/cancer [2A00-2F9Z] [22]
Ifosfamide DMCT3I8 Moderate Increased plasma concentrations of Tacrolimus and Ifosfamide due to competitive inhibition of the same metabolic pathway. Solid tumour/cancer [2A00-2F9Z] [22]
Docetaxel DMDI269 Moderate Increased plasma concentrations of Tacrolimus and Docetaxel due to competitive inhibition of the same metabolic pathway. Solid tumour/cancer [2A00-2F9Z] [22]
Armodafinil DMGB035 Moderate Increased metabolism of Tacrolimus caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [21]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Tacrolimus and LEE011. Solid tumour/cancer [2A00-2F9Z] [24]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Tacrolimus and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [24]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [29]
Taxol DMUOT9V Moderate Increased plasma concentrations of Tacrolimus and Taxol due to competitive inhibition of the same metabolic pathway. Solid tumour/cancer [2A00-2F9Z] [22]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [24]
Telavancin DM58VQX Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [22]
Pomalidomide DMTGBAX Moderate Decreased metabolism of Tacrolimus caused by Pomalidomide mediated inhibition of CYP450 enzyme. Systemic sclerosis [4A42] [21]
Fostamatinib DM6AUHV Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [88]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [89]
Apixaban DM89JLN Moderate Decreased clearance of Tacrolimus due to the transporter inhibition by Apixaban. Thrombosis [DB61-GB90] [29]
Brilinta DMBR01X Moderate Decreased metabolism of Tacrolimus caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [29]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Lenvatinib. Thyroid cancer [2D10] [24]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Tacrolimus and Cabozantinib. Thyroid cancer [2D10] [29]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Tacrolimus and Papaverine. Tonus and reflex abnormality [MB47] [90]
Olsalazine DMZW9HA Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Olsalazine. Ulcerative colitis [DD71] [22]
Plazomicin DMKMBES Major Increased risk of nephrotoxicity by the combination of Tacrolimus and Plazomicin. Urinary tract infection [GC08] [22]
Elagolix DMB2C0E Moderate Increased metabolism of Tacrolimus caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [21]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [91]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Tacrolimus and Procainamide. Ventricular tachyarrhythmia [BC71] [24]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Propafenone. Ventricular tachyarrhythmia [BC71] [24]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Tacrolimus and Flecainide. Ventricular tachyarrhythmia [BC71] [24]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Tacrolimus and Amiodarone. Ventricular tachyarrhythmia [BC71] [24]
Ganciclovir DM1MBYQ Moderate Increased risk of nephrotoxicity by the combination of Tacrolimus and Ganciclovir. Virus infection [1A24-1D9Z] [21]
Valganciclovir DMS2IUH Moderate Increased risk of lowers seizure threshold by the combination of Tacrolimus and Valganciclovir. Virus infection [1A24-1D9Z] [21]
⏷ Show the Full List of 283 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Butylated hydroxytoluene E00336 31404 Antioxidant
D&C red no. 28 E00491 6097185 Colorant
D&C red no. 33 E00261 19116 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Poloxamer 188 E00645 Not Available Emulsifying agent; Solubilizing agent; Surfactant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Potassium hydroxide E00233 14797 Alkalizing agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Tartaric acid E00029 875 Acidulant; Complexing agent; Flavoring agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 25 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Tacrolimus 0.75 mg tablet 0.75 mg 24 HR Extended Release Oral Tablet Oral
Tacrolimus 1 mg tablet 1 mg 24 HR Extended Release Oral Tablet Oral
Tacrolimus 4 mg tablet 4 mg 24 HR Extended Release Oral Tablet Oral
Tacrolimus 1 mg capsule 1 mg Oral Capsule Oral
Tacrolimus 0.5 mg capsule 0.5 mg Oral Capsule Oral
Tacrolimus 5 mg capsule 5 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Tacrolimus FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6784).
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Figueroa DB, Tillotson J, Li M, Piwowar-Manning E, Hendrix CW, Holtz TH, Bokoch K, Bekker LG, van Griensven F, Mannheimer S, Hughes JP, Grant RM, Bumpus NN: Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067. PLoS One. 2018 Apr 11;13(4):e0195764. doi: 10.1371/journal.pone.0195764. eCollection 2018.
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8 Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20.
9 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
10 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
11 Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol. 2007 Aug;21(4):427-35.
12 Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy. Pharmacogenet Genomics. 2017 Sep;27(9):337-346.
13 High frequency of macrolide resistance mechanisms in clinical isolates of Corynebacterium species. Microb Drug Resist. 2010 Dec;16(4):273-7.
14 Calcineurin is an important factor involved in glucose uptake in human adipocytes. Mol Cell Biochem. 2018 Aug;445(1-2):157-168. doi: 10.1007/s11010-017-3261-0. Epub 2018 Jan 27.
15 Immunosuppressive calcineurin inhibitor cyclosporine A?induces proapoptotic endoplasmic reticulum stress in renal tubular cells. J Biol Chem. 2022 Mar;298(3):101589. doi: 10.1016/j.jbc.2022.101589. Epub 2022 Jan 14.
16 Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation. 2002 Aug 27;74(4):571-2. doi: 10.1097/00007890-200208270-00024.
17 CyclinB2 and BIRC5 genes as surrogate biomarkers for neurite outgrowth in SH-SY5Y subclonal cells. Neuropharmacology. 2006 Jun;50(8):1041-7. doi: 10.1016/j.neuropharm.2006.02.004. Epub 2006 Mar 30.
18 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
19 Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis. Br J Dermatol. 2005 Jun;152(6):1173-81. doi: 10.1111/j.1365-2133.2005.06474.x.
20 GSK3, snail, and adhesion molecule regulation by cyclosporine A in renal tubular cells. Toxicol Sci. 2012 Jun;127(2):425-37. doi: 10.1093/toxsci/kfs108. Epub 2012 Mar 12.
21 Cerner Multum, Inc. "Australian Product Information.".
22 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
23 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
24 Canadian Pharmacists Association.
25 Multum Information Services, Inc. Expert Review Panel.
26 Bhaloo S, Prasad GV "Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: a case report." Transplant Proc 35 (2003): 2449-51. [PMID: 14611983]
27 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
28 Herzig K, Johnson DW "Marked elevation of blood cyclosporine and tacrolimus levels due to concurrent metronidazole therapy." Nephrol Dial Transplant 14 (1999): 521-3. [PMID: 10069238]
29 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
30 Seifeldin RA, Marcos-Alvarez A, Gordon FD, Lewis WD, Jenkins R "Nifedipine interaction with tacrolimus in liver transplant recipients." Ann Pharmacother 31 (1997): 571-5. [PMID: 9161650]
31 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
32 Albengres E, Le Louet H, Tillement JP "Systemic antifungal agents. Drug interactions of clinical significance." Drug Saf 18 (1998): 83-97. [PMID: 9512916]
33 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
34 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
35 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
36 Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77. [PMID: 11103749]
37 FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).".
38 Cakaloglu Y, Tredger JM, Devlin J, Williams R "Importance of cytochrome p-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients." Hepatology 20 (1994): 309-16. [PMID: 7519161]
39 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
40 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
41 Barshes NR, Goodpastor SE, Goss JA "Sirolimus-atorvastatin drug interaction in the pancreatic islet transplant recipient." Transplantation 76 (2003): 1649-50. [PMID: 14702546]
42 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
43 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
44 Product Information. Dificid (fidaxomicin). Optimer Pharmaceuticals, San Diego, CA.
45 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
46 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
47 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
48 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
49 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
50 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
51 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
52 Product Information. ORAVIG (miconazole). Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.
53 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
54 Barau C, Blouin P, Creput C, Taburet AM, Durrbach A, Furlan V "Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient." Fundam Clin Pharmacol 23 (2009): 423-5. [PMID: 19709321]
55 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
56 Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
57 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
58 Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14. [PMID: 10996582]
59 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
60 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
61 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
62 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
63 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
64 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
65 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
66 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
67 Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
68 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
69 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
70 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
71 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
72 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
73 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
74 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
75 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
76 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
77 Prescott WA Jr, Callahan BL, Park JM "Tacrolimus toxicity associated with concomitant metoclopramide therapy." Pharmacotherapy 24 (2004): 532-7. [PMID: 15098810]
78 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
79 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
80 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
81 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
82 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
83 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
84 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
85 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
86 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
87 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
88 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
89 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
90 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
91 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]